BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021;397:375-86. [PMID: 33485464 DOI: 10.1016/S0140-6736(20)32714-8] [Cited by in Crossref: 314] [Cited by in F6Publishing: 343] [Article Influence: 157.0] [Reference Citation Analysis]
Number Citing Articles
1 van Gulijk M, Belderbos B, Dumoulin D, Cornelissen R, Bezemer K, Klaase L, Dammeijer F, Aerts J. Combination of PD-1/PD-L1 checkpoint inhibition and dendritic cell therapy in mice models and in patients with mesothelioma. Int J Cancer 2023;152:1438-43. [PMID: 36104949 DOI: 10.1002/ijc.34293] [Reference Citation Analysis]
2 Cangemi M, Montico M, Trovo M, Minatel E, Di Gregorio E, Corona G, Giordari F, Comaro E, Colizzi F, Baboçi L, Steffan A, Revelant A, Muraro E. Emerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy. Int J Radiat Oncol Biol Phys 2023;115:608-21. [PMID: 36202181 DOI: 10.1016/j.ijrobp.2022.09.079] [Reference Citation Analysis]
3 Nguyen NT, Mitsuhashi A, Ogino H, Kozai H, Yoneda H, Afroj T, Sato S, Nokihara H, Shinohara T, Nishioka Y. S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor. Cancer Sci 2023;114:384-98. [PMID: 36285504 DOI: 10.1111/cas.15620] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sakura K, Sasai M, Funaki S, Shintani Y, Okumura M, Kaneda Y. Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study. Cancers 2023;15:929. [DOI: 10.3390/cancers15030929] [Reference Citation Analysis]
5 Paajanen J, Jaklitsch MT, Bueno R. Contemporary issues in the surgical management of pleural mesothelioma. J Surg Oncol 2023;127:343-54. [PMID: 36630097 DOI: 10.1002/jso.27152] [Reference Citation Analysis]
6 Cunningham R, Jia S, Purohit K, Salem O, Hui NS, Lin Y, Carragher NO, Hansen CG. YAP/TAZ activation predicts clinical outcomes in mesothelioma and is conserved in in vitro model of driver mutations. Clin Transl Med 2023;13:e1190. [PMID: 36740402 DOI: 10.1002/ctm2.1190] [Reference Citation Analysis]
7 Yaman Ortaköylü M, İncesoy Özdemir S, Dinçaslan H, Taçyıldız N, Ünal AE, Soydal Ç, Fitöz ÖS, Ünal E. Nivolumab for pediatric malignant peritoneal mesothelioma. Pediatr Blood Cancer 2023;70:e29892. [PMID: 35851543 DOI: 10.1002/pbc.29892] [Reference Citation Analysis]
8 Ni JJ, Zhang ZZ, Ge MJ, Chen JY, Zhuo W. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights. Acta Pharmacol Sin 2023;44:288-307. [PMID: 35927312 DOI: 10.1038/s41401-022-00953-z] [Reference Citation Analysis]
9 Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, Splawn T, Espinoza M, Almarez M, Hosey L, Jo E, Hilsenbeck S, Amos CI, Ripley RT, Burt BM. A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res 2023;29:548-59. [PMID: 36469573 DOI: 10.1158/1078-0432.CCR-22-2566] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhou H, Jia W, Lu L, Han R. MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment. Cancers 2023;15:824. [DOI: 10.3390/cancers15030824] [Reference Citation Analysis]
11 Di Genova A, Mangiante L, Sexton-Oates A, Voegele C, Fernandez-Cuesta L, Alcala N, Foll M. A molecular phenotypic map of malignant pleural mesothelioma. Gigascience 2022;12. [PMID: 36705549 DOI: 10.1093/gigascience/giac128] [Reference Citation Analysis]
12 Perrino M, De Vincenzo F, Cordua N, Borea F, Aliprandi M, Santoro A, Zucali PA. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress. Front Immunol 2023;14. [DOI: 10.3389/fimmu.2023.1121557] [Reference Citation Analysis]
13 Huo G, Liu W, Zhang S, Chen P. Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis. Immunotherapy 2023. [PMID: 36683533 DOI: 10.2217/imt-2022-0140] [Reference Citation Analysis]
14 Ries A, Flehberger D, Slany A, Pirker C, Mader JC, Mohr T, Schelch K, Sinn K, Mosleh B, Hoda MA, Dome B, Dolznig H, Krupitza G, Müllauer L, Gerner C, Berger W, Grusch M. Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin. J Exp Clin Cancer Res 2023;42:27. [PMID: 36683050 DOI: 10.1186/s13046-022-02582-0] [Reference Citation Analysis]
15 Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother 2023. [PMID: 36633661 DOI: 10.1007/s00262-022-03349-4] [Reference Citation Analysis]
16 Kiya Y, Yoshioka Y, Nagakawa Y, Ochiya T. Extracellular Vesicles Are Important Mediators That Regulate Tumor Lymph Node Metastasis via the Immune System. Int J Mol Sci 2023;24. [PMID: 36674900 DOI: 10.3390/ijms24021362] [Reference Citation Analysis]
17 Pandey GK, Landman N, Neikes HK, Hulsman D, Lieftink C, Beijersbergen R, Kolluri KK, Janes SM, Vermeulen M, Badhai J, van Lohuizen M. Genetic screens reveal new targetable vulnerabilities in BAP1-deficient mesothelioma. Cell Rep Med 2023;:100915. [PMID: 36657447 DOI: 10.1016/j.xcrm.2022.100915] [Reference Citation Analysis]
18 Katsuya Y, Kitano S, Yamashita M, Ouchi M, Yagishita S, Hamada A, Nakamura H, Hosoda F, Shibata T, Motoi N, Nakayama T, Seto T, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Ohe Y, Horinouchi H. Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma. Front Oncol 2022;12:966527. [PMID: 36698400 DOI: 10.3389/fonc.2022.966527] [Reference Citation Analysis]
19 Nakamura A, Hashimoto M, Kondo N, Matsumoto S, Kuroda A, Minami T, Kitajima K, Kuribayashi K, Kijima T, Hasegawa S. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention. Int J Clin Oncol 2023. [PMID: 36609928 DOI: 10.1007/s10147-023-02292-3] [Reference Citation Analysis]
20 Cerbone L, Delfanti S, De Angelis AM, Crivellari S, Boccuzzi F, Cimorelli A, Bertolotti M, Righi L, Bertino P, Grosso F. Unprecedented long-term survival in a patient with malignant pleural mesothelioma treated with subsequent systemic chemo- and immunotherapeutic regimens. Thorac Cancer 2023. [PMID: 36599413 DOI: 10.1111/1759-7714.14789] [Reference Citation Analysis]
21 Stern E, Caruso S, Meiller C, Mishalian I, Hirsch TZ, Bayard Q, Tadmor CT, Wald H, Jean D, Wald O. Deep dive into the immune response against murine mesothelioma permits design of novel anti-mesothelioma therapeutics. Front Immunol 2022;13:1026185. [PMID: 36685577 DOI: 10.3389/fimmu.2022.1026185] [Reference Citation Analysis]
22 Balasubramanian A, John T. Safety of Dueling NSCLC With Dual Agent Immunotherapy. J Thorac Oncol 2023;18:10-3. [PMID: 36543429 DOI: 10.1016/j.jtho.2022.10.009] [Reference Citation Analysis]
23 Nief CA, No HJ, Louie CY, Vitzthum L, Das M. Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series. Clin Lung Cancer 2023;24:76-81. [PMID: 36323592 DOI: 10.1016/j.cllc.2022.10.002] [Reference Citation Analysis]
24 Shu Y, Ding Y, Li F, Zhang Q. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer. Int Immunopharmacol 2023;114:109589. [PMID: 36700770 DOI: 10.1016/j.intimp.2022.109589] [Reference Citation Analysis]
25 Foster JM, Zhang C, Rehman S, Sharma P, Alexander HR. The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J Clin 2023;73:49-71. [PMID: 35969103 DOI: 10.3322/caac.21749] [Reference Citation Analysis]
26 Paz-Ares LG, Ciuleanu TE, Pluzanski A, Lee JS, Gainor JF, Otterson GA, Audigier-Valette C, Ready N, Schenker M, Linardou H, Caro RB, Provencio M, Zurawski B, Lee KH, Kim SW, Caserta C, Ramalingam SS, Spigel DR, Brahmer JR, Reck M, O'Byrne KJ, Girard N, Popat S, Peters S, Memaj A, Nathan F, Aanur N, Borghaei H. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. J Thorac Oncol 2023;18:79-92. [PMID: 36049658 DOI: 10.1016/j.jtho.2022.08.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Lengyel CG. Mechanisms of Resistance to Immunotherapies in Cancer. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_335-1] [Reference Citation Analysis]
28 Zhang D, Liang J, Lv Y, Huang X, Guo W. Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma. Medicine (Baltimore) 2022;101:e32459. [PMID: 36596035 DOI: 10.1097/MD.0000000000032459] [Reference Citation Analysis]
29 Marini W, Wilson BE, Reedijk M. Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer. DNA Cell Biol 2022. [PMID: 36579947 DOI: 10.1089/dna.2022.0578] [Reference Citation Analysis]
30 Mansur A, Potter A, Zurovec AJ, Nathamuni KV, Meyerhoff RR, Berry MF, Kang A, Jeffrey Yang CF. An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma. Chest 2022:S0012-3692(22)04340-9. [PMID: 36574925 DOI: 10.1016/j.chest.2022.12.019] [Reference Citation Analysis]
31 Singh A, Busacca S, Gaba A, Sheaff M, Poile C, Nakas A, Dzialo J, Bzura A, Dawson AG, Fennell DA, Fry AM. BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms. Oncogene 2022. [PMID: 36550359 DOI: 10.1038/s41388-022-02577-3] [Reference Citation Analysis]
32 Wang L, Xu H, Weng L, Sun J, Jin Y, Xiao C. Activation of cancer immunotherapy by nanomedicine. Front Pharmacol 2022;13:1041073. [PMID: 36618938 DOI: 10.3389/fphar.2022.1041073] [Reference Citation Analysis]
33 Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol 2022;4:579-97. [PMID: 36636451 DOI: 10.1016/j.jaccao.2022.09.004] [Reference Citation Analysis]
34 Ripley RT, Holmes HM, Whitlock RS, Groth SS, Medina CG, Choi EA, Burt BM, Sugarbaker PH. Pleurectomy and decortication are associated with better survival for bicavitary cytoreductive surgery for mesothelioma compared with extrapleural pneumonectomy. J Thorac Cardiovasc Surg 2022:S0022-5223(22)01338-1. [PMID: 36740497 DOI: 10.1016/j.jtcvs.2022.11.035] [Reference Citation Analysis]
35 Zhou N, Bell CS, Feldman HA, Haymaker CL, Hofstetter WL, Tsao AS, Mehran RJ, Rice DC, Sepesi B; Mesothelioma Immune Genomic Group. Tumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival. J Thorac Cardiovasc Surg 2022:S0022-5223(22)01337-X. [PMID: 36737380 DOI: 10.1016/j.jtcvs.2022.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Meirson T, Nardone V, Pentimalli F, Markel G, Bomze D, D’apolito M, Correale P, Giordano A, Pirtoli L, Porta C, Gray SG, Mutti L. Analysis of new treatments proposed for malignant pleural mesothelioma raises concerns about the conduction of clinical trials in oncology. J Transl Med 2022;20:593. [DOI: 10.1186/s12967-022-03744-6] [Reference Citation Analysis]
37 Vicier C, Isambert N, Cropet C, Hamimed M, Osanno L, Legrand F, de La Motte Rouge T, Ciccolini J, Gonçalves A. MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. ESMO Open 2022;7:100646. [PMID: 36521418 DOI: 10.1016/j.esmoop.2022.100646] [Reference Citation Analysis]
38 Zhang Z, Rafei-Shamsabadi D, Lehr S, Buettner N, Diehl R, Huzly D, Pinato DJ, Thimme R, Meiss F, Bengsch B. Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity. J Transl Med 2022;20:582. [PMID: 36503532 DOI: 10.1186/s12967-022-03755-3] [Reference Citation Analysis]
39 Jin H, Wang L, Bernards R. Rational combinations of targeted cancer therapies: background, advances and challenges. Nat Rev Drug Discov 2022. [PMID: 36509911 DOI: 10.1038/s41573-022-00615-z] [Reference Citation Analysis]
40 Shi H, Zhang L, Yu T, Zheng L, Ke H, Johnson B, Rath E, Lee K, Klebe S, Kao S, Qin KL, Pham HNT, Vuong Q, Cheng YY. Leptospermum extract (QV0) suppresses pleural mesothelioma tumour growthin vitroandin vivoby mitochondrial dysfunction associated apoptosis.. [DOI: 10.1101/2022.12.06.519377] [Reference Citation Analysis]
41 Gemelli M, Cortinovis DL, Baggi A, di Mauro P, Calza S, Berruti A, Grisanti S, Rota M. Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2022;14. [PMID: 36551550 DOI: 10.3390/cancers14246063] [Reference Citation Analysis]
42 Martin C, Enrico D. Current and novel therapeutic strategies for optimizing immunotherapy outcomes in advanced non-small cell lung cancer. Front Oncol 2022;12:962947. [PMID: 36568253 DOI: 10.3389/fonc.2022.962947] [Reference Citation Analysis]
43 Ruan Z, Zhang Y, Quan Q, Jiang J, Wang Q, Zhang Y, Peng R. Pan-cancer analysis identifies DDX56 as a prognostic biomarker associated with immune infiltration and drug sensitivity. Front Genet 2022;13:1004467. [PMID: 36568395 DOI: 10.3389/fgene.2022.1004467] [Reference Citation Analysis]
44 Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-richter U, Kiyota N, Roberts M, Khan TA, Miller-moslin K, Wei L, Argiris A. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. JCO 2022. [DOI: 10.1200/jco.22.00332] [Reference Citation Analysis]
45 Voronova V, Vislobokova A, Mutig K, Samsonov M, Peskov K, Sekacheva M, Materenchuk M, Bunyatyan N, Lebedeva S. Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. Front Oncol 2022;12:1035884. [PMID: 36544712 DOI: 10.3389/fonc.2022.1035884] [Reference Citation Analysis]
46 Ferreira M. Épanchement pleural malin : des pistes de recherche intéressantes pour le diagnostic, le pronostic et la prise en charge. Revue des Maladies Respiratoires Actualités 2022;14:2S455-2S460. [DOI: 10.1016/s1877-1203(22)00780-7] [Reference Citation Analysis]
47 Canova S, Ceresoli GL, Grosso F, Zucali PA, Gelsomino F, Pasello G, Mencoboni M, Rulli E, Galli F, De Simone I, Carlucci L, De Angelis A, Belletti M, Bonomi M, D'Aveni A, Perrino M, Bono F, Cortinovis DL; DIADEM groupD. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. ESMO Open 2022;7:100644. [PMID: 36463732 DOI: 10.1016/j.esmoop.2022.100644] [Reference Citation Analysis]
48 Banks KC, Ossowski S, Hung YY, Hsu DS, Ashiku SK, Patel AR, Velotta JB, Suga JM. Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System. Clin Lung Cancer 2022;23:694-701. [PMID: 36216742 DOI: 10.1016/j.cllc.2022.09.003] [Reference Citation Analysis]
49 Abedi Kiasari B, Abbasi A, Ghasemi Darestani N, Adabi N, Moradian A, Yazdani Y, Sadat Hosseini G, Gholami N, Janati S. Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy. International Immunopharmacology 2022;113:109365. [DOI: 10.1016/j.intimp.2022.109365] [Reference Citation Analysis]
50 Rizzolo A, Ah-Lan KC, Nu TNT, Alcindor T. Response to Ipilimumab and Nivolumab in a Patient With Malignant Peritoneal Mesothelioma. Clin Colorectal Cancer 2022;21:371-4. [PMID: 36055919 DOI: 10.1016/j.clcc.2022.08.001] [Reference Citation Analysis]
51 Davis KL, Fox E, Isikwei E, Reid JM, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL. A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412. Clin Cancer Res 2022;28:5088-97. [PMID: 36190525 DOI: 10.1158/1078-0432.CCR-22-2164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Moro J, Sobrero S, Cartia CF, Ceraolo S, Rapanà R, Vaisitti F, Ganio S, Mellone F, Rudella S, Scopis F, La Paglia D, Cacciatore CC, Ruffini E, Leo F. Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma. Diagnostics (Basel) 2022;12. [PMID: 36553016 DOI: 10.3390/diagnostics12123009] [Reference Citation Analysis]
53 Nash AM, Aghlara-Fotovat S, Castillio B, Hernandez A, Pugazenthi A, Lee HS, Jang HJ, Nguyen A, Lu A, Burt BM, Ghanta RK, Veiseh O. Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors. Clin Cancer Res 2022;28:5121-35. [PMID: 35993913 DOI: 10.1158/1078-0432.CCR-22-1493] [Reference Citation Analysis]
54 Terenziani R, Galetti M, La Monica S, Fumarola C, Zoppi S, Alfieri R, Digiacomo G, Cavazzoni A, Cavallo D, Corradi M, Tiseo M, Petronini PG, Bonelli M. CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells. Cancers (Basel) 2022;14. [PMID: 36497412 DOI: 10.3390/cancers14235925] [Reference Citation Analysis]
55 Barnett SE, Herrmann A, Shaw L, Gash EN, Poptani H, Sacco JJ, Coulson JM. The Chick Embryo Xenograft Model for Malignant Pleural Mesothelioma: A Cost and Time Efficient 3Rs Model for Drug Target Evaluation. Cancers (Basel) 2022;14. [PMID: 36497318 DOI: 10.3390/cancers14235836] [Reference Citation Analysis]
56 Barbolina TD, Bagrova SG. New stage in evolution of drug treatment of pleural mesothelioma. Medicinskij alfavit 2022. [DOI: 10.33667/2078-5631-2022-26-27-30] [Reference Citation Analysis]
57 Brown LJ, da Silva IP, Moujaber T, Gao B, Hui R, Gurney H, Carlino M, Nagrial A. Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres. Cancer Medicine 2022. [DOI: 10.1002/cam4.5468] [Reference Citation Analysis]
58 Sundaralingam A, Aujayeb A, Akca B, Tiedeman C, George V, Carling M, Brown J, Banka R, Addala D, Bedawi EO, Hallifax RJ, Iqbal B, Denniston P, Tsakok MT, Kanellakis NI, Vafai-Tabrizi F, Bergman M, Funk GC, Benamore RE, Wrightson JM, Rahman NM. Achieving Molecular Profiling in Pleural Biopsies: A Multicenter, Retrospective Cohort Study. Chest 2022:S0012-3692(22)04169-1. [PMID: 36410492 DOI: 10.1016/j.chest.2022.11.019] [Reference Citation Analysis]
59 Strange CD, Marom EM, Ahuja J, Shroff GS, Gladish GW, Carter BW, Truong MT. Imaging of Malignant Pleural, Pericardial, and Peritoneal Mesothelioma. Advances in Anatomic Pathology 2022;Publish Ahead of Print. [DOI: 10.1097/pap.0000000000000386] [Reference Citation Analysis]
60 Graham PT, Nowak AK, Cornwall SMJ, Larma I, Nelson DJ. The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.969678] [Reference Citation Analysis]
61 Osmanbeyoglu HU, Palmer D, Sagan A, Sementino E, Becich MJ, Testa JR. Isolated BAP1 Genomic Alteration in Malignant Pleural Mesothelioma Predicts Distinct Immunogenicity with Implications for Immunotherapeutic Response. Cancers (Basel) 2022;14. [PMID: 36428720 DOI: 10.3390/cancers14225626] [Reference Citation Analysis]
62 Andrini E, Federico AD, Sisi M, Rosellini M, Palladini A, Lamberti G, Giglio AD, Gelsomino F. Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. Immunotherapy 2022. [DOI: 10.2217/imt-2022-0060] [Reference Citation Analysis]
63 Offin M, Sauter JL, Tischfield SE, Egger JV, Chavan S, Shah NS, Manoj P, Ventura K, Allaj V, de Stanchina E, Travis W, Ladanyi M, Rimner A, Rusch VW, Adusumilli PS, Poirier JT, Zauderer MG, Rudin CM, Sen T. Genomic and transcriptomic analysis of a diffuse pleural mesothelioma patient-derived xenograft library. Genome Med 2022;14:127. [PMID: 36380343 DOI: 10.1186/s13073-022-01129-4] [Reference Citation Analysis]
64 O’connor GM, Bakker EY. Patient-Level Omics Data Analysis Identifies Gene-Specific Survival Associations for a PD-1/PD-L1 Network in Pleural Mesothelioma. BioMedInformatics 2022;2:580-592. [DOI: 10.3390/biomedinformatics2040037] [Reference Citation Analysis]
65 Nahar KJ, Marsh-Wakefield F, Rawson RV, Gide TN, Ferguson AL, Allen R, Quek C, da Silva IP, Tattersal S, Kiely CJ, Sandanayake N, Carlino MS, McCaughan G, Wilmott JS, Scolyer RA, Long GV, Menzies AM, Palendira U. Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. JCI Insight 2022;7. [PMID: 36173679 DOI: 10.1172/jci.insight.157839] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Suzuki K, Tange M, Yamagishi R, Hanada H, Mukai S, Sato T, Tanaka T, Akashi T, Kadomatsu K, Maeda T, Miida T, Takeuchi I, Murakami H, Sekido Y, Murakami-Tonami Y. SMG6 regulates DNA damage and cell survival in Hippo pathway kinase LATS2-inactivated malignant mesothelioma. Cell Death Discov 2022;8:446. [PMID: 36335095 DOI: 10.1038/s41420-022-01232-w] [Reference Citation Analysis]
67 Hanada K, Tsunoda S, Nomura M, Fujimura S, Yutaka Y, Nishigori T, Hisamori S, Maekewa H, Hoshino N, Itami A, Tanaka E, Obama K. A case of long-term survival treated with three metastasectomies and two subsequent adjuvant nivolumab therapies for recurrent malignant melanoma of the esophagus. surg case rep 2022;8:206. [DOI: 10.1186/s40792-022-01561-z] [Reference Citation Analysis]
68 Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N. First-in-human study of ONO-4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors. Cancer Sci 2023;114:211-20. [PMID: 36082616 DOI: 10.1111/cas.15574] [Reference Citation Analysis]
69 Paajanen J, Bueno R, De Rienzo A. The Rocky Road from Preclinical Findings to Successful Targeted Therapy in Pleural Mesothelioma. IJMS 2022;23:13422. [DOI: 10.3390/ijms232113422] [Reference Citation Analysis]
70 Leal JL, Hoang W, Xue J, Dunne B, John T, Harden S. What's Current and What's New in Mesothelioma? Clin Oncol (R Coll Radiol) 2022;34:771-80. [PMID: 36155156 DOI: 10.1016/j.clon.2022.08.029] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Conway RJH, Symonds J, Walton D, Probets J, Comins C, Stadon L, Harvey JE, Blyth KG, Maskell NA, Bibby AC. Protocol for a prospective observational cohort study collecting data on demographics, symptoms and biomarkers in people with mesothelioma (ASSESS-meso). BMJ Open 2022;12:e060850. [DOI: 10.1136/bmjopen-2022-060850] [Reference Citation Analysis]
72 Chang F, Keam S, Hoang TS, Creaney J, Gill S, Nowak AK, Ebert M, Cook AM. Immune marker expression of irradiated mesothelioma cell lines. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1020493] [Reference Citation Analysis]
73 Chernova T, Grosso S, Sun X, Tenor AR, Cabeza JZ, Craxton A, Self EL, Nakas A, Cain K, Macfarlane M, Willis AE. Extracellular Vesicles Isolated from Malignant Mesothelioma Cancer-Associated Fibroblasts Induce Pro-Oncogenic Changes in Healthy Mesothelial Cells. IJMS 2022;23:12469. [DOI: 10.3390/ijms232012469] [Reference Citation Analysis]
74 Jiménez-Ramírez C, Gilbert Weber D, Aguilar-Madrid G, Brik A, Juárez-Pérez CA, Casjens S, Raiko I, Brüning T, Johnen G, Cabello-López A. Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis. PLoS One 2022;17:e0275936. [PMID: 36240245 DOI: 10.1371/journal.pone.0275936] [Reference Citation Analysis]
75 Wheatley-Price P. Access to Cancer Drugs in Canada. Curr Oncol 2022;29:7583-6. [PMID: 36290875 DOI: 10.3390/curroncol29100598] [Reference Citation Analysis]
76 Zhao B, Zhang F, Wang Y, Chen G, Nie M, Zhao Z, Chen X, Jiang K, Nie R, Chen Y. LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials. Cancers 2022;14:4975. [DOI: 10.3390/cancers14204975] [Reference Citation Analysis]
77 Hashimoto K, Kaira K. History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. The Journal of the Japan Broncho-esophagological Society 2022;73:325-331. [DOI: 10.2468/jbes.73.325] [Reference Citation Analysis]
78 Chen S, Yu W, Shao S, Xiao J, Bai H, Pu Y, Li M. Establishment of predictive nomogram and web-based survival risk calculator for malignant pleural mesothelioma: A SEER database analysis. Front Oncol 2022;12:1027149. [DOI: 10.3389/fonc.2022.1027149] [Reference Citation Analysis]
79 Yang K, Yang T, Yang T, Yuan Y, Li F. Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination. Front Oncol 2022;12:995651. [DOI: 10.3389/fonc.2022.995651] [Reference Citation Analysis]
80 . Mesothelioma. Fundamentals of Cancer Detection, Treatment, and Prevention 2022. [DOI: 10.1002/9783527838561.ch13] [Reference Citation Analysis]
81 Nishimura T, Ninomiya K, Nakashima M, Akagi S, Kuribayashi T, Higo H, Hotta K, Maeda Y, Ito H, Kiura K. Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy: A Case Report. Intern Med 2022. [PMID: 36130891 DOI: 10.2169/internalmedicine.0505-22] [Reference Citation Analysis]
82 Okita R, Mimura-kimura Y, Kawamoto N, Yamamoto N, Umeda M, Okada M, Inokawa H, Mimura Y, Murakami T, Nakata M, Okabe K. Effects of tumor-infiltrating CD8+ T cells, PD1/PD-L1 axis, and expression patterns of HLA class I on the prognosis of patients with malignant pleural mesothelioma who underwent extra-pleural pneumonectomy. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03292-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Ries A, Flehberger D, Slany A, Pirker C, Mader JC, Mohr T, Schelch K, Sinn K, Mosleh B, Hoda MA, Dome B, Dolznig H, Krupitza G, Gerner C, Berger W, Grusch M. Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin.. [DOI: 10.21203/rs.3.rs-2045206/v1] [Reference Citation Analysis]
84 Tedesco J, Jaradeh M, Vigneswaran WT. Malignant Pleural Mesothelioma: Current Understanding of the Immune Microenvironment and Treatments of a Rare Disease. Cancers (Basel) 2022;14:4415. [PMID: 36139575 DOI: 10.3390/cancers14184415] [Reference Citation Analysis]
85 Kepenekian V, Bhatt A, Péron J, Alyami M, Benzerdjeb N, Bakrin N, Falandry C, Passot G, Rousset P, Glehen O. Advances in the management of peritoneal malignancies. Nat Rev Clin Oncol 2022. [PMID: 36071285 DOI: 10.1038/s41571-022-00675-5] [Reference Citation Analysis]
86 Mishra AK, Ali A, Dutta S, Banday S, Malonia SK. Emerging Trends in Immunotherapy for Cancer. Diseases 2022;10:60. [DOI: 10.3390/diseases10030060] [Reference Citation Analysis]
87 Zhang T, Wang Y, Shi C, Liu X, Lv S, Wang X, Li W. Pancreatic injury following immune checkpoint inhibitors: A systematic review and meta-analysis. Front Pharmacol 2022;13:955701. [DOI: 10.3389/fphar.2022.955701] [Reference Citation Analysis]
88 Offin M, De Silva D, Sauter JL, Egger JV, Yorke E, Adusumilli PS, Rimner A, Rusch VW, Zauderer MG. Brief Report: Multimodality Therapy in Patients with Primary Pericardial Mesothelioma. J Thorac Oncol 2022:S1556-0864(22)01561-1. [PMID: 36075530 DOI: 10.1016/j.jtho.2022.08.017] [Reference Citation Analysis]
89 Disselhorst MJ, Lubeck Y, van der Noort V, Quispel-Janssen J, Seignette IM, Sanders J, Peters D, Hooijberg E, Baas P. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab? Lung Cancer 2022;173:49-52. [PMID: 36122471 DOI: 10.1016/j.lungcan.2022.08.019] [Reference Citation Analysis]
90 Trassl L, Stathopoulos GT. KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player. Cancers (Basel) 2022;14:4303. [PMID: 36077838 DOI: 10.3390/cancers14174303] [Reference Citation Analysis]
91 Kajiyama K, Taira A, Takenaka M, Kuroda K, Kusano M, Nawata A, Tanaka F. Salvage Pleurectomy/Decortication After Immunotherapy for Sarcomatoid Malignant Pleural Mesothelioma. Annals of Thoracic Surgery Short Reports 2022. [DOI: 10.1016/j.atssr.2022.07.004] [Reference Citation Analysis]
92 Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen D, Berglund A, Michael L, Aoki M, Wang M, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. The Lancet 2022;400:1008-19. [DOI: 10.1016/s0140-6736(22)01659-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Orozco Morales ML, Rinaldi CA, de Jong E, Lansley SM, Gary Lee YC, Zemek RM, Bosco A, Lake RA, Lesterhuis WJ. Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma.. [DOI: 10.1101/2022.08.29.505655] [Reference Citation Analysis]
94 Gregório PHP, Terra RM, Lima LP, Pêgo-Fernandes PM. Mesothelioma in a developing country: a retrospective analysis of the diagnostic process. J Bras Pneumol 2022;48:e20220064. [PMID: 36000688 DOI: 10.36416/1806-3756/e20220064] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Ranzato E, Bonsignore G, Martinotti S. ER Stress Response and Induction of Apoptosis in Malignant Pleural Mesothelioma: The Achilles Heel Targeted by the Anticancer Ruthenium Drug BOLD-100. Cancers 2022;14:4126. [DOI: 10.3390/cancers14174126] [Reference Citation Analysis]
96 Fennell DA, Bzura A. Accelerating innovations in systemic therapy for pleural mesothelioma. Nat Cancer 2022;3:902-904. [DOI: 10.1038/s43018-022-00419-5] [Reference Citation Analysis]
97 Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, Zhang L, Hu J, Luo P, Zhang J, Liu Z, Peng Y, Liu Z, Tang L, Cheng Q. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol 2022;15:111. [PMID: 35978433 DOI: 10.1186/s13045-022-01325-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
98 Yang L, Cao X, Li N, Zheng B, Liu M, Cai H. Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as the first-line treatment for unresectable malignant pleural mesothelioma. Ther Adv Med Oncol 2022;14:17588359221116604. [PMID: 35958872 DOI: 10.1177/17588359221116604] [Reference Citation Analysis]
99 Gemelli M, Cortinovis DL, Baggi A, Mauro PD, Calza S, Grisanti S, Rota M. Immune- Checkpoint Inhibitors in Malignant Pleural Mesothelioma: a meta-analysis.. [DOI: 10.21203/rs.3.rs-1936101/v1] [Reference Citation Analysis]
100 Kiss I, Kuhn M, Hrusak K, Buchler B, Boublikova L, Buchler T. Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. Front Oncol 2022;12:946307. [DOI: 10.3389/fonc.2022.946307] [Reference Citation Analysis]
101 Gao Y, Kruithof-de Julio M, Peng R, Dorn P. Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today? Cancers 2022;14:3758. [DOI: 10.3390/cancers14153758] [Reference Citation Analysis]
102 Chen C, Sun P, Long J. Robust and durable response to first-line treatment of pembrolizumab combined with chemotherapy in two patients with metastatic thymic squamous cell carcinoma: Case report. Front Immunol 2022;13:941092. [DOI: 10.3389/fimmu.2022.941092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Hasegawa M, Hanamatsu Y, Saigo C, Kito Y, Takeuchi T. Tumor suppressor effect of an antibody on xenotransplanted sarcomatoid mesothelioma cells. Thorac Cancer 2022. [PMID: 35916358 DOI: 10.1111/1759-7714.14591] [Reference Citation Analysis]
104 van Zandwijk N, Rasko JEJ, George AM, Frank AL, Reid G. The silent malignant mesothelioma epidemic: a call to action. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00269-8] [Reference Citation Analysis]
105 Flury DV, Kocher GJ. Epidemiologie, Diagnostik und Therapie des Pleuramesothelioms. InFo Hämatol Onkol 2022;25:40-61. [DOI: 10.1007/s15004-022-9127-y] [Reference Citation Analysis]
106 Moutafi MK, Molero M, Martinez Morilla S, Baena J, Vathiotis IA, Gavrielatou N, Castro-Labrador L, de Garibay GR, Adradas V, Orive D, Valencia K, Calvo A, Montuenga LM, Ponce Aix S, Schalper KA, Herbst RS, Paz-Ares L, Rimm DL, Zugazagoitia J. Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer. J Immunother Cancer 2022;10:e004757. [PMID: 36002182 DOI: 10.1136/jitc-2022-004757] [Reference Citation Analysis]
107 Røe OD, Creaney J; BAP1 Study Group. Response to "Revisiting 'BAP1ness' in Malignant Pleural Mesothelioma". J Thorac Oncol 2022;17:e69-70. [PMID: 35931425 DOI: 10.1016/j.jtho.2022.05.013] [Reference Citation Analysis]
108 Jha A, Ward T, Walker S, Goodwin AT, Chalmers JD. Review of the British Thoracic Society Winter Meeting 2021, 24-26 November 2021. Thorax 2022:thoraxjnl-2022-219150. [PMID: 35907640 DOI: 10.1136/thorax-2022-219150] [Reference Citation Analysis]
109 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
110 Wang S, Yang Y, Li L, Ma P, Jiang Y, Ge M, Yu Y, Huang H, Fang Y, Jiang N, Miao H, Guo H, Yan L, Ren Y, Sun L, Zha Y, Li N. Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development. Vaccines (Basel) 2022;10:1168. [PMID: 35893817 DOI: 10.3390/vaccines10081168] [Reference Citation Analysis]
111 Ye Z, Tang Z, Xu Z, Zhou Q, Li H. Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma. Front Public Health 2022;10:947375. [DOI: 10.3389/fpubh.2022.947375] [Reference Citation Analysis]
112 Tian Y, Zhang C, Dang Q, Wang K, Liu Q, Liu H, Shang H, Zhao J, Xu Y, Wu T, Liu W, Yang X, Safi M, Wu YS. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/4976032] [Reference Citation Analysis]
113 Mannarino L, Mirimao F, Panini N, Paracchini L, Marchini S, Beltrame L, Amodeo R, Grosso F, Libener R, De Simone I, Ceresoli GL, Zucali PA, Lupi M, D'Incalci M. Tumor treating fields affect mesothelioma cell proliferation by exerting histotype-dependent cell cycle checkpoint activations and transcriptional modulations. Cell Death Dis 2022;13:612. [PMID: 35840560 DOI: 10.1038/s41419-022-05073-4] [Reference Citation Analysis]
114 Ramarao-Milne P, Kondrashova O, Patch AM, Nones K, Koufariotis LT, Newell F, Addala V, Lakis V, Holmes O, Leonard C, Wood S, Xu Q, Mukhopadhyay P, Naeini MM, Steinfort D, Williamson JP, Bint M, Pahoff C, Nguyen PT, Twaddell S, Arnold D, Grainge C, Basirzadeh F, Fielding D, Dalley AJ, Chittoory H, Simpson PT, Aoude LG, Bonazzi VF, Patel K, Barbour AP, Fennell DA, Robinson BW, Creaney J, Hollway G, Pearson JV, Waddell N. Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. ESMO Open 2022;7:100540. [PMID: 35849877 DOI: 10.1016/j.esmoop.2022.100540] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
115 Bedirhan MA, Seyrek Y, Yaran V, Sezen CB, Cansever L, Metin M. Does mediastinal lymph node involvement influence the surgical outcome in malign pleural mesothelioma? Acta Chir Belg 2022;:1-8. [PMID: 35815370 DOI: 10.1080/00015458.2022.2099558] [Reference Citation Analysis]
116 Hagiyama M, Mimae T, Wada A, Takeuchi F, Yoneshige A, Inoue T, Kotoku N, Hamada H, Sekido Y, Okada M, Ito A. Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma. Front Cell Dev Biol 2022;10:945007. [DOI: 10.3389/fcell.2022.945007] [Reference Citation Analysis]
117 Choudhury H, Budde J, Ahmed N, Johnson A, Adewunmi C. Saved by the Scan: A Case of Early Detection of Sarcomatoid Mesothelioma. Cureus 2022. [DOI: 10.7759/cureus.26793] [Reference Citation Analysis]
118 Lynggård LA, Panou V, Szejniuk W, Røe OD, Meristoudis C. Diagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma. J Am Soc Cytopathol 2022:S2213-2945(22)00067-9. [PMID: 35945149 DOI: 10.1016/j.jasc.2022.07.003] [Reference Citation Analysis]
119 Liu S, Gao W, Ning Y, Zou X, Zhang W, Zeng L, Liu J. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:908173. [DOI: 10.3389/fimmu.2022.908173] [Reference Citation Analysis]
120 Okita R, Okada M, Inokawa H, Murakami T, Ikeda E. Prognostic values of preoperative C-reactive protein, albumin, and neutrophil ratios in patients with malignant pleural mesothelioma who underwent extrapleural pneumonectomy. Surg Oncol 2022;43:101813. [PMID: 35816852 DOI: 10.1016/j.suronc.2022.101813] [Reference Citation Analysis]
121 Dubois F, Bazille C, Levallet J, Maille E, Brosseau S, Madelaine J, Bergot E, Zalcman G, Levallet G. Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP. Target Oncol 2022;17:407-31. [PMID: 35906513 DOI: 10.1007/s11523-022-00900-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Ghafoor A, Hassan R. Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy. J Thorac Oncol 2022;17:862-4. [PMID: 35750452 DOI: 10.1016/j.jtho.2022.05.005] [Reference Citation Analysis]
123 Fennell DA, Dulloo S, Harber J. Immunotherapy approaches for malignant pleural mesothelioma. Nat Rev Clin Oncol 2022. [PMID: 35778611 DOI: 10.1038/s41571-022-00649-7] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
124 Tanaka T, Asakura S, Hisamatsu K, Fujimoto N. Thrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report. JTO Clinical and Research Reports 2022;3:100351. [DOI: 10.1016/j.jtocrr.2022.100351] [Reference Citation Analysis]
125 Du K, Zou J, Wang B, Liu C, Khan M, Xie T, Huang X, Shen P, Tian Y, Yuan Y. A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma. Front Immunol 2022;13:857934. [DOI: 10.3389/fimmu.2022.857934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Cortiula F, Reymen B, Peters S, Van Mol P, Wauters E, Vansteenkiste J, De Ruysscher D, Hendriks LEL. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches. Ann Oncol 2022:S0923-7534(22)01742-2. [PMID: 35777706 DOI: 10.1016/j.annonc.2022.06.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Zhao X, Gao F, Yang J, Fan H, Xie Q, Jiang K, Gong J, Gao B, Yang Q, Lei Z. Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis. Front Oncol 2022;12:877434. [DOI: 10.3389/fonc.2022.877434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 van Kooten JP, Dietz MV, Guchelaar NAD, Brandt-Kerkhof ARM, Koolen SLW, Burger JWA, Mathijssen RHJ, Verhoef C, Aerts JGJV, Madsen EVE. Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO. BMJ Open 2022;12:e062907. [PMID: 35732399 DOI: 10.1136/bmjopen-2022-062907] [Reference Citation Analysis]
129 Bellini A, Aramini B, Stella F. Surgical Management of Malignant Pleural Mesothelioma: From the Past to the Future. Mesothelioma - Diagnostics, Treatment and Basic Research [Working Title] 2022. [DOI: 10.5772/intechopen.103686] [Reference Citation Analysis]
130 Ollila H, Mäyränpää MI, Paavolainen L, Paajanen J, Välimäki K, Sutinen E, Wolff H, Räsänen J, Kallioniemi O, Myllärniemi M, Ilonen I, Pellinen T. Prognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma. Front Oncol 2022;12:870352. [DOI: 10.3389/fonc.2022.870352] [Reference Citation Analysis]
131 Kuryk L, Rodella G, Staniszewska M, Pancer KW, Wieczorek M, Salmaso S, Caliceti P, Garofalo M. Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects. Front Oncol 2022;12:916839. [DOI: 10.3389/fonc.2022.916839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Jurmeister P, Leitheiser M, Wolkenstein P, Klauschen F, Capper D, Brcic L. DNA methylation-based machine learning classification distinguishes pleural mesothelioma from chronic pleuritis, pleural carcinosis, and pleomorphic lung carcinomas. Lung Cancer 2022;170:105-13. [PMID: 35749951 DOI: 10.1016/j.lungcan.2022.06.008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
133 Offin M, Rusch VW, Rimner A, Adusumilli PS, Zauderer MG. Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice. Oncologist 2022:oyac113. [PMID: 35708504 DOI: 10.1093/oncolo/oyac113] [Reference Citation Analysis]
134 Gill S, Nowak AK, Bowyer S, Endersby R, Ebert MA, Cook A. Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR). J Med Imaging Radiat Oncol 2022. [PMID: 35699321 DOI: 10.1111/1754-9485.13441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
135 Kulkarni NS, Gupta V. Repurposing therapeutics for malignant pleural mesothelioma (MPM) - Updates on clinical translations and future outlook. Life Sci 2022;304:120716. [PMID: 35709894 DOI: 10.1016/j.lfs.2022.120716] [Reference Citation Analysis]
136 Fujiwara Y, Takahashi Y, Okada M, Kishimoto T, Kondo S, Fujikawa K, Hayama M, Sugeno M, Ueda S, Komuro K, Lanasa M, Nakano T. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma. Oncologist 2022:oyac099. [PMID: 35671201 DOI: 10.1093/oncolo/oyac099] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. J Immunother Cancer 2022;10:e003956. [PMID: 35640927 DOI: 10.1136/jitc-2021-003956] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Sanmamed MF, Berraondo P, Rodriguez-ruiz ME, Melero I. Charting roadmaps towards novel and safe synergistic immunotherapy combinations. Nat Cancer 2022;3:665-680. [DOI: 10.1038/s43018-022-00401-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Fennell DA, Porter C, Lester J, Danson S, Taylor P, Sheaff M, Rudd RM, Gaba A, Busacca S, Nixon L, Gardner G, Darlison L, Poile C, Richards C, Jordan P, Griffiths G, Casbard A. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. eClinicalMedicine 2022;48:101432. [DOI: 10.1016/j.eclinm.2022.101432] [Reference Citation Analysis]
140 Kiss I, Kuhn M, Hrusak K, Buchler T. Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. ESMO Open 2022;7:100474. [DOI: 10.1016/j.esmoop.2022.100474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Dagogo-Jack I, Madison RW, Lennerz JK, Chen KT, Hopkins JF, Schrock AB, Ritterhouse LL, Lester A, Wharton KA Jr, Mino-Kenudson M, Danziger N, Hung YP, Mata DA, Ross JS. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape. JCO Precis Oncol 2022;6:e2100422. [PMID: 35704798 DOI: 10.1200/PO.21.00422] [Reference Citation Analysis]
142 Nong C, Guan P, Li L, Zhang H, Hu H. Tumor immunotherapy: Mechanisms and clinical applications. MedComm – Oncology 2022;1. [DOI: 10.1002/mog2.8] [Reference Citation Analysis]
143 Iranzo P, Callejo A, Assaf JD, Molina G, Lopez DE, Garcia-illescas D, Pardo N, Navarro A, Martinez-marti A, Cedres S, Carbonell C, Frigola J, Amat R, Felip E. Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. Front Med 2022;9:875974. [DOI: 10.3389/fmed.2022.875974] [Reference Citation Analysis]
144 Creaney J, Patch A, Addala V, Sneddon SA, Nones K, Dick IM, Lee YCG, Newell F, Rouse EJ, Naeini MM, Kondrashova O, Lakis V, Nakas A, Waller D, Sharkey A, Mukhopadhyay P, Kazakoff SH, Koufariotis LT, Davidson AL, Ramarao-milne P, Holmes O, Xu Q, Leonard C, Wood S, Grimmond SM, Bueno R, Fennell DA, Pearson JV, Robinson BW, Waddell N. Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma. Genome Med 2022;14. [DOI: 10.1186/s13073-022-01060-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Xiang Z, Li J, Zhang Z, Cen C, Chen W, Jiang B, Meng Y, Wang Y, Berglund B, Zhai G, Wu J. Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. Front Pharmacol 2022;13:883655. [DOI: 10.3389/fphar.2022.883655] [Reference Citation Analysis]
146 Sandach P, Seifert R, Fendler WP, Hautzel H, Herrmann K, Maier S, Plönes T, Metzenmacher M, Ferdinandus J. A Role for PET/CT in response assessment of malignant pleural mesothelioma. Semin Nucl Med 2022:S0001-2998(22)00039-3. [PMID: 35624033 DOI: 10.1053/j.semnuclmed.2022.04.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
147 Mannarino L, Paracchini L, Pezzuto F, Olteanu GE, Moracci L, Vedovelli L, De Simone I, Bosetti C, Lupi M, Amodeo R, Inglesi A, Callari M, Penpa S, Libener R, Delfanti S, De Angelis A, Muzio A, Zucali PA, Allavena P, Ceresoli GL, Marchini S, Calabrese F, D'Incalci M, Grosso F. Epithelioid Pleural Mesothelioma Is Characterized by Tertiary Lymphoid Structures in Long Survivors: Results from the MATCH Study. Int J Mol Sci 2022;23:5786. [PMID: 35628597 DOI: 10.3390/ijms23105786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
148 Nabeshima K, Hamasaki M, Kinoshita Y, Matsumoto S, Sa-Ngiamwibool P. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations. Pathol Int 2022. [PMID: 35596704 DOI: 10.1111/pin.13235] [Reference Citation Analysis]
149 Spieler B, Giret TM, Welford S, Totiger TM, Mihaylov IB. Lung Inflammation Predictors in Combined Immune Checkpoint-Inhibitor and Radiation Therapy—Proof-of-Concept Animal Study. Biomedicines 2022;10:1173. [DOI: 10.3390/biomedicines10051173] [Reference Citation Analysis]
150 Wang Z, Yang H, Luo B, Duan P, Lin P. NFE2L3 as a Novel Biomarker Associated With IL-2/STAT5/NLRP3 Signaling Pathway in Malignant Pleural Mesothelioma and Other Cancers. Front Genet 2022;13:805256. [DOI: 10.3389/fgene.2022.805256] [Reference Citation Analysis]
151 Tostes FT, Zugman M, Paes VR, Schvartsman G. Complete Pathological Response After Neoadjuvant Chemo-Immunotherapy in Malignant Pleural Mesothelioma. Front Oncol 2022;12:836751. [PMID: 35574305 DOI: 10.3389/fonc.2022.836751] [Reference Citation Analysis]
152 Anobile DP, Montenovo G, Pecoraro C, Franczak M, Ait Iddouch W, Peters GJ, Riganti C, Giovannetti E. Splicing deregulation, microRNA and Notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma. Expert Review of Clinical Pharmacology. [DOI: 10.1080/17512433.2022.2074835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
153 Bronte G, Procopio AD, Graciotti L. The application of cancer stem cell model in malignant mesothelioma. Crit Rev Oncol Hematol 2022;:103698. [PMID: 35525390 DOI: 10.1016/j.critrevonc.2022.103698] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Zucali PA, De Vincenzo F, Perrino M, Digiacomo N, Cordua N, D'Antonio F, Borea F, Fazio R, Pirozzi A, Santoro A. Advances in Drug Treatments for Mesothelioma. Expert Opin Pharmacother 2022. [PMID: 35508368 DOI: 10.1080/14656566.2022.2072211] [Reference Citation Analysis]
155 Kawahira M, Kanmura S, Mizuno K, Machida K, Ohtsuka T, Sato M, Enokida H, Yamashita M, Kanekura T, Arima S, Nakamura N, Sugiura T, Yoshimoto K, Kobayashi H, Ishitsuka K, Suzuki S, Ueno S, Ido A. Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events. PLoS One 2022;17:e0267572. [PMID: 35482642 DOI: 10.1371/journal.pone.0267572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
156 Choi AY, Singh A, Wang D, Pittala K, Hoang CD. Current State of Pleural-Directed Adjuncts Against Malignant Pleural Mesothelioma. Front Oncol 2022;12:886430. [DOI: 10.3389/fonc.2022.886430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Luigi Banna G, Addeo A, Zygoura P, Tsourti Z, Popat S, Curioni-fontecedro A, Nadal E, Shah R, Pope A, Fisher P, Spicer J, Roy A, Gilligan D, Gautschi O, Janthur W, López-castro R, Roschitzki-voser H, Dafni U, Peters S, Stahel RA. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.05.018] [Reference Citation Analysis]
158 Scherpereel A, Crépin F. Immunothérapie et autres stratégies dans le traitement du mésothéliome pleural. Revue des Maladies Respiratoires Actualités 2022;14:1S9-1S17. [DOI: 10.1016/s1877-1203(22)00008-8] [Reference Citation Analysis]
159 Liu L, Hui R, Zeng T, Yang X, Wu Q, Yang T. CUL4B is a Potential Novel Prognostic Biomarker and is Correlated with Immune Infiltrates in Malignant Pleural Mesothelioma. IJGM 2022;Volume 15:4613-23. [DOI: 10.2147/ijgm.s355889] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
160 Banna GL, Signori A, Curioni-fontecedro A, Cortellini A, Ponzano M, Giunta EF, Rebuzzi SE, Chan S, Gebbia V, van Eeden R, Addeo A, Ottensmeier C. Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. European Journal of Cancer 2022;166:287-99. [DOI: 10.1016/j.ejca.2022.02.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Starzer AM, Preusser M, Berghoff AS. Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. Ther Adv Med Oncol 2022;14:175883592210962. [DOI: 10.1177/17588359221096219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
162 De Fonseka D, Arnold DT, Morley AJ, Brett M, Bhatt N, Edey A, Daly R, Bibby AC, Maskell NA. Lymphocyte predominance in blood, pleural fluid, and tumour stroma; a prognostic marker in pleural mesothelioma. BMC Pulm Med 2022;22:173. [PMID: 35501755 DOI: 10.1186/s12890-022-01968-2] [Reference Citation Analysis]
163 Holzknecht A, Illini O, Hochmair MJ, Krenbek D, Setinek U, Huemer F, Bitterlich E, Kaindl C, Getman V, Akan A, Weber M, Leobacher G, Valipour A, Mueller MR, Watzka SB. Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients. Cancers 2022;14:2245. [DOI: 10.3390/cancers14092245] [Reference Citation Analysis]
164 Hoyos C, Fontaine A, Jacques JR, Heinen V, Louis R, Duysinx B, Scherpereel A, Wasielewski E, Jamakhani M, Hamaidia M, Willems L. HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells. Cancers (Basel) 2022;14:2164. [PMID: 35565292 DOI: 10.3390/cancers14092164] [Reference Citation Analysis]
165 Mielgo-Rubio X, Cardeña Gutiérrez A, Sotelo Peña V, Sánchez Becerra MV, González López AM, Rosero A, Trujillo-Reyes JC, Couñago F. Tsunami of immunotherapy reaches mesothelioma. World J Clin Oncol 2022; 13(4): 267-275 [DOI: 10.5306/wjco.v13.i4.267] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Yanagitani N. Combination Immunotherapy in the First-line Setting for Non-small-cell Lung Cancer. JJLC 2022;62:75-80. [DOI: 10.2482/haigan.62.75] [Reference Citation Analysis]
167 Momal R, Trichelair P, Blum MG, Balazard F. More efficient and inclusive time-to-event trials with covariate adjustment: a simulation study.. [DOI: 10.1101/2022.04.15.22273871] [Reference Citation Analysis]
168 Govindarajan A, Castro DV, Zengin ZB, Salgia SK, Patel J, Pal SK. Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions. Cancers (Basel) 2022;14:2049. [PMID: 35565179 DOI: 10.3390/cancers14092049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Kutuk T, Appel H, Avendano MC, Albrecht F, Kaywin P, Ramos S, Suarez-murias ME, Mehta MP, Kotecha R. Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data. Cancers 2022;14:2020. [DOI: 10.3390/cancers14082020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
170 Nair NU, Jiang Q, Wei JS, Misra VA, Morrow B, Kesserwan C, Hermida LC, Lee JS, Mian I, Zhang J, Lebensohn A, Sengupta M, Khan J, Ruppin E, Hassan R. Transcriptomics based prediction of survival and response to therapy in malignant mesothelioma.. [DOI: 10.1101/2022.04.13.488207] [Reference Citation Analysis]
171 Messori A, Trippoli S. Current treatments for inoperable mesothelioma: indirect comparisons based on individual patient data reconstructed retrospectively from 4 trials. J Chemother 2022;:1-5. [PMID: 35411826 DOI: 10.1080/1120009X.2022.2061183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
172 Liu YY, Ding CZ, Chen JL, Wang ZS, Yang B, Wu XM. A Novel Small Molecular Inhibitor of DNMT1 Enhances the Antitumor Effect of Radiofrequency Ablation in Lung Squamous Cell Carcinoma Cells. Front Pharmacol 2022;13:863339. [PMID: 35401185 DOI: 10.3389/fphar.2022.863339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
173 Paternot S, Raspé E, Meiller C, Tarabichi M, Assié J, Libert F, Remmelink M, Bisteau X, Pauwels P, Blum Y, Le Stang N, Tabone-eglinger S, Galateau-sallé F, Blanquart C, Van Meerbeeck JP, Berghmans T, Jean D, Roger PP. Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition.. [DOI: 10.1101/2022.04.11.487857] [Reference Citation Analysis]
174 Ogasawara S, Koroki K, Makishima H, Wakatsuki M, Takahashi A, Yumita S, Nakagawa M, Ishino T, Ogawa K, Fujiwara K, Iwanaga T, Sakuma T, Fujita N, Kojima R, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Ozawa Y, Kawasaki Y, Kurokawa T, Hanaoka H, Tsuji H, Kato N. Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ Open 2022;12:e059779. [PMID: 35396315 DOI: 10.1136/bmjopen-2021-059779] [Reference Citation Analysis]
175 Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, Shalaby MN, Thangavelu L, Kamrava S, Shomali N, Sohrabi AD, Adili A, Noroozi-Aghideh A, Razeghian E. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal 2022;20:44. [PMID: 35392976 DOI: 10.1186/s12964-022-00854-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 35.0] [Reference Citation Analysis]
176 Zauderer MG, Offin M. ARCS-M: forging progress from this negative trial in malignant pleural mesothelioma. The Lancet Oncology 2022;23:445-6. [DOI: 10.1016/s1470-2045(22)00099-7] [Reference Citation Analysis]
177 Wheatley-price P, Moore S, Lee CW. The Role of Real-World Evidence to Support Treatment Choices in Malignant Pleural Mesothelioma. JTO Clinical and Research Reports 2022;3:100300. [DOI: 10.1016/j.jtocrr.2022.100300] [Reference Citation Analysis]
178 Sun B, Dong Y, Xu J, Wang Z. Current status and progress in immunotherapy for malignant pleural mesothelioma. Chronic Diseases and Translational Medicine. [DOI: 10.1002/cdt3.18] [Reference Citation Analysis]
179 Rubio-infante N, Ramírez-flores YA, Castillo EC, Lozano O, García-rivas G, Torre-amione G. A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety. Front Cell Dev Biol 2022;10:851032. [DOI: 10.3389/fcell.2022.851032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
180 Li CY, Kennedy T, Alexander HR. Treatment of Patients with Malignant Peritoneal Mesothelioma. J Clin Med 2022;11:1891. [PMID: 35407498 DOI: 10.3390/jcm11071891] [Reference Citation Analysis]
181 Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses? Cancers (Basel) 2022;14:1710. [PMID: 35406483 DOI: 10.3390/cancers14071710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Mathilakathu A, Wessolly M, Mairinger E, Uebner H, Kreidt D, Brcic L, Steinborn J, Greimelmaier K, Wohlschlaeger J, Schmid KW, Mairinger FD, Borchert S. Cancer-Associated Fibroblasts Regulate Kinase Activity in Mesothelioma Cell Lines via Paracrine Signaling and Thereby Dictate Cell Faith and Behavior. Int J Mol Sci 2022;23:3278. [PMID: 35328699 DOI: 10.3390/ijms23063278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
183 Liu Y, Zhao D. A novel nano-immunotherapeutic remodels the immune landscape of malignant pleural effusion: Insights into its mechanism of action through single-cell RNA-sequencing. Clin Transl Med 2022;12:e774. [PMID: 35297203 DOI: 10.1002/ctm2.774] [Reference Citation Analysis]
184 Massafra R, Catino A, Perrotti PMS, Pizzutilo P, Fanizzi A, Montrone M, Galetta D. Informative Power Evaluation of Clinical Parameters to Predict Initial Therapeutic Response in Patients with Advanced Pleural Mesothelioma: A Machine Learning Approach. J Clin Med 2022;11:1659. [PMID: 35329985 DOI: 10.3390/jcm11061659] [Reference Citation Analysis]
185 Assié JB, Crépin F, Grolleau E, Canellas A, Geier M, Grébert-Manuardi A, Akkache N, Renault A, Hauss PA, Sabatini M, Bonnefoy V, Cortot A, Wislez M, Gauvain C, Chouaïd C, Scherpereel A, Monnet I. Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World Study. Cancers (Basel) 2022;14:1498. [PMID: 35326648 DOI: 10.3390/cancers14061498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Rovers S, Janssens A, Raskin J, Pauwels P, van Meerbeeck JP, Smits E, Marcq E. Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma. Biomedicines 2022;10:673. [PMID: 35327475 DOI: 10.3390/biomedicines10030673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
187 Davis A, Ke H, Kao S, Pavlakis N. An Update on Emerging Therapeutic Options for Malignant Pleural Mesothelioma. Lung Cancer (Auckl) 2022;13:1-12. [PMID: 35264891 DOI: 10.2147/LCTT.S288535] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Pasello G, Remon J, Felley-bosco E. Editorial: Understanding the Interplay Between the Tumor Immune Microenvironment and Genetic Alterations in Thoracic Malignancies. Front Oncol 2022;12:871544. [DOI: 10.3389/fonc.2022.871544] [Reference Citation Analysis]
189 Shahzad MH, Feng L, Su X, Brassard A, Dhoparee-Doomah I, Ferri LE, Spicer JD, Cools-Lartigue JJ. Neutrophil Extracellular Traps in Cancer Therapy Resistance. Cancers (Basel) 2022;14:1359. [PMID: 35267667 DOI: 10.3390/cancers14051359] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
190 Shitara K, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli AC, Liu T, Tehfe M, Elimova E, Bruges R, Zander T, de Azevedo S, Kowalyszyn R, Pazo-Cid R, Schenker M, Cleary JM, Yanez P, Feeney K, Karamouzis MV, Poulart V, Lei M, Xiao H, Kondo K, Li M, Janjigian YY. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 2022;603:942-8. [PMID: 35322232 DOI: 10.1038/s41586-022-04508-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 15.0] [Reference Citation Analysis]
191 Kunishige M, Kondo Y, Kadota N, Okano Y, Machida H, Hatakeyama N, Hino H, Naruse K, Shinohara T, Sakiyama S, Takeuchi E. Favorable response to nivolumab in sarcomatoid malignant pleural mesothelioma: A case report. Current Problems in Cancer: Case Reports 2022;5:100138. [DOI: 10.1016/j.cpccr.2022.100138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
192 Cedres S, Felip E. 3-year CheckMate743 outcomes: ringing in immunotherapy for the treatment of malignant pleural mesothelioma. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.03.004] [Reference Citation Analysis]
193 Kosari F, Disselhorst M, Yin J, Peikert T, Udell J, Johnson S, Smadbeck J, Murphy S, McCune A, Karagouga G, Desai A, Schaefer-Klein J, Borad MJ, Cheville J, Vasmatzis G, Baas P, Mansfield AS. Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. J Thorac Oncol 2022;17:446-54. [PMID: 34800701 DOI: 10.1016/j.jtho.2021.10.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
194 Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, Mckenna M, Baas P. First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.03.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
195 Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, Krstic-Demonacos M, Markel G, Giordano A, Bomze D, Mutti L. Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma. JAMA Netw Open 2022;5:e221490. [PMID: 35262715 DOI: 10.1001/jamanetworkopen.2022.1490] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
196 Tsao AS, Pass HI, Rimner A, Mansfield AS. New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J Clin Oncol 2022;40:681-92. [PMID: 34985934 DOI: 10.1200/JCO.21.01567] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
197 Stinchcombe TE, Bradley JD. Thoracic Oncology: Current Standard Therapy and Future Developments. J Clin Oncol 2022;40:527-9. [PMID: 34985922 DOI: 10.1200/JCO.21.02396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
198 Shi J, Lai D, Zuo X, Liu D, Chen B, Zheng Y, Lu C, Gu X. Identification of Ferroptosis-Related Biomarkers for Prognosis and Immunotherapy in Patients With Glioma. Front Cell Dev Biol 2022;10:817643. [PMID: 35174152 DOI: 10.3389/fcell.2022.817643] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
199 Shah R, Klotz LV, Glade J. Current Management and Future Perspective in Pleural Mesothelioma. Cancers (Basel) 2022;14:1044. [PMID: 35205798 DOI: 10.3390/cancers14041044] [Reference Citation Analysis]
200 Takei S, Kawazoe A, Shitara K. The New Era of Immunotherapy in Gastric Cancer. Cancers (Basel) 2022;14:1054. [PMID: 35205802 DOI: 10.3390/cancers14041054] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
201 Perryman L, Gray SG. Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases. Cancers (Basel) 2022;14:981. [PMID: 35205728 DOI: 10.3390/cancers14040981] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
202 Rittberg R, Chan E, Yip S, Alex D, Ho C. Radiation Induced Abscopal Effect in a Patient With Malignant Pleural Mesothelioma on Pembrolizumab. Cureus 2022. [DOI: 10.7759/cureus.22159] [Reference Citation Analysis]
203 Konwar M, Bose D, Maurya M, Ravi R. A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis. J Oncol Pharm Pract 2022;:10781552221074315. [PMID: 35147454 DOI: 10.1177/10781552221074315] [Reference Citation Analysis]
204 van Kooten JP, Belderbos RA, von der Thüsen JH, Aarts MJ, Verhoef C, Burgers JA, Baas P, Aalbers AGJ, Maat APWM, Aerts JGJV, Cornelissen R, Madsen EVE. Incidence, treatment and survival of malignant pleural and peritoneal mesothelioma: a population-based study. Thorax 2022:thoraxjnl-2021-217709. [PMID: 35149582 DOI: 10.1136/thoraxjnl-2021-217709] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Amano Y, Sakura KL, Ohta S, Ito T. Cisplatin-Chelated Iminodiacetic Acid-Conjugated Hyaluronic Acid Nanogels for the Treatment of Malignant Pleural Mesothelioma in Mice. Mol Pharm 2022. [PMID: 35142223 DOI: 10.1021/acs.molpharmaceut.1c00797] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
206 Louw A, van Vliet C, Peverall J, Colkers S, Acott N, Creaney J, Lee YCG, Chai SM. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology. Cancer Cytopathol 2022. [PMID: 35143119 DOI: 10.1002/cncy.22548] [Reference Citation Analysis]
207 Štrbac D, Dolžan V. Novel and Future Treatment Options in Mesothelioma: A Systematic Review. Int J Mol Sci 2022;23:1975. [PMID: 35216091 DOI: 10.3390/ijms23041975] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
208 Kefas J, Harwood C, Lewis MJ, Szlosarek P. Small vessel vasculitis and dry gangrene secondary to combined CTLA-4 and PD-1 blockade in malignant mesothelioma. BMC Rheumatol 2022;6. [DOI: 10.1186/s41927-021-00238-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Carloni R, Rizzo A, Ricci AD, Frega G, Federico AD, Palloni A, Marco MD, Gadaleta-Caldarola G, Brandi G. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? Future Oncol 2022. [PMID: 35109664 DOI: 10.2217/fon-2021-0905] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
210 Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu C, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang W, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 2022;386:449-62. [DOI: 10.1056/nejmoa2111380] [Cited by in Crossref: 64] [Cited by in F6Publishing: 90] [Article Influence: 64.0] [Reference Citation Analysis]
211 Kidd AC, Anderson O, Cowell GW, Weir AJ, Voisey JP, Evison M, Tsim S, Goatman KA, Blyth KG. Fully automated volumetric measurement of malignant pleural mesothelioma by deep learning AI: validation and comparison with modified RECIST response criteria. Thorax 2022:thoraxjnl-2021-217808. [PMID: 35110367 DOI: 10.1136/thoraxjnl-2021-217808] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
212 Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan M, Talbot T, Monnet I, Hiret S, Baas P, Nowak A, Fujimoto N, Tsao A, Mansfield A, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology 2022. [DOI: 10.1016/j.annonc.2022.01.074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
213 Tagliamento M, Bironzo P, Curcio H, De Luca E, Pignataro D, Rapetti SG, Audisio M, Bertaglia V, Paratore C, Bungaro M, Olmetto E, Artusio E, Reale ML, Zichi C, Capelletto E, Carnio S, Buffoni L, Passiglia F, Novello S, Scagliotti GV, Di Maio M. A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103639] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
214 Breen LJ, Huseini T, Same A, Peddle-mcintyre CJ, Lee YG. Living with Mesothelioma: A Systematic Review of Patient and Caregiver Psychosocial Support Needs. Patient Education and Counseling 2022. [DOI: 10.1016/j.pec.2022.02.017] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
215 O’byrne K, Lee K, Kim S, Park K, Nishio M, Sakai H, Ohe Y, Fukuhara T, Kang J, Daga H, Yu C, Hotta K, Tanaka H, Takeda M, Yokoyama T, Nathan F, Lee J. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients. ESMO Open 2022;7:100394. [DOI: 10.1016/j.esmoop.2022.100394] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
216 Onishi F, Fujimoto N. Recent Advances in Systemic Therapy for Malignant Pleural Mesothelioma: Focus on Anti-Angiogenic Inhibitors and Immune Checkpoint Inhibitors. Mesothelioma - Diagnostics, Treatment and Basic Research [Working Title] 2022. [DOI: 10.5772/intechopen.102511] [Reference Citation Analysis]
217 Kok PS, Forde PM, Hughes B, Sun Z, Brown C, Ramalingam S, Cook A, Lesterhuis WJ, Yip S, O'Byrne K, Pavlakis N, Brahmer J, Anagnostou V, Ford K, Fitzpatrick K, Bricker A, Cummins MM, Stockler M, Nowak AK; Thoracic Oncology Group of Australasia (TOGA) and PrECOG, USA. Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. BMJ Open 2022;12:e057663. [PMID: 35078853 DOI: 10.1136/bmjopen-2021-057663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
218 Lapidot M, Saladi SV, Salgia R, Sattler M. Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma. Front Pharmacol 2021;12:806570. [PMID: 35069219 DOI: 10.3389/fphar.2021.806570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
219 Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21. [DOI: 10.1186/s12943-021-01489-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 47.0] [Reference Citation Analysis]
220 Endo I, Amatya VJ, Kushitani K, Kambara T, Nakagiri T, Fujii Y, Takeshima Y. Insulin-Like Growth Factor 2 mRNA Binding Protein 3 Promotes Cell Proliferation of Malignant Mesothelioma Cells by Downregulating p27Kip1. Front Oncol 2022;11:795467. [DOI: 10.3389/fonc.2021.795467] [Reference Citation Analysis]
221 Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, Marchetti A, Battelli N, Massari F. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol 2022;170:103596. [PMID: 35031442 DOI: 10.1016/j.critrevonc.2022.103596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Yang H, Berezowska S, Dorn P, Zens P, Chen P, Peng RW, Marti TM, Kocher GJ, Schmid RA, Hall SRR. Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma. Theranostics 2022;12:167-85. [PMID: 34987640 DOI: 10.7150/thno.61209] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Pezzicoli G, Rizzo M, Perrone M, Minei S, Mutti L, Porta C. A Glimpse in the Future of Malignant Mesothelioma Treatment. Front Pharmacol 2021;12:809337. [PMID: 34975505 DOI: 10.3389/fphar.2021.809337] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
224 Cantini L, Laniado I, Murthy V, Sterman D, G.j.v. Aerts J. Immunotherapy for mesothelioma: moving beyond single immune check point inhibition. Lung Cancer 2022. [DOI: 10.1016/j.lungcan.2022.01.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
225 Liu W, Liu C, Wang H, Xu L, Zhou J, Li S, Cheng Y, Zhou R, Zhao L. Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy. Computational and Structural Biotechnology Journal 2022;20:5150-61. [DOI: 10.1016/j.csbj.2022.09.017] [Reference Citation Analysis]
226 Picciotto D, Genova C, Costigliolo F, Bottini A, Garibotto G, Viazzi F, Esposito P. An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_80] [Reference Citation Analysis]
227 Moiseev A, Guriyanova A, Suntsova M, Buzdin A, Sorokin M. A case of whole-exome and transcriptome sequencing of tumor for personalized experimental treatment for metastatic mesothelioma. Onkol Z im P A Gercena 2022;11:62. [DOI: 10.17116/onkolog20221102162] [Reference Citation Analysis]
228 Berling M, Chaudhary MA, Yuan Y, Varol N, Dale P, Testa E, Klint J, Lee A, Lubinga SJ, Penrod JR. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States. J Med Econ 2022;25:703-11. [PMID: 35659172 DOI: 10.1080/13696998.2022.2077549] [Reference Citation Analysis]
229 Graziani G, Lisi L, Tentori L, Navarra P. Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum 2022. [DOI: 10.1007/978-3-030-91311-3_10] [Reference Citation Analysis]
230 Pasquarelli-do-nascimento G, Machado SA, de Carvalho JMA, Magalhães KG. Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy. Immunotherapy Advances 2022;2. [DOI: 10.1093/immadv/ltac015] [Reference Citation Analysis]
231 Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply. The Lancet Oncology 2022;23:e14-5. [DOI: 10.1016/s1470-2045(21)00722-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
232 Scherpereel A, Crepin F. Malignant Pleural Mesothelioma. Encyclopedia of Respiratory Medicine 2022. [DOI: 10.1016/b978-0-08-102723-3.00156-6] [Reference Citation Analysis]
233 Remon J, Facchinetti F, Besse B. The efficacy of immune checkpoint inhibitors in thoracic malignancies. Eur Respir Rev 2021;30:200387. [PMID: 34615702 DOI: 10.1183/16000617.0387-2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Schillebeeckx E, van Meerbeeck JP, Lamote K. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis. Eur Respir Rev 2021;30:210057. [PMID: 34789461 DOI: 10.1183/16000617.0057-2021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
235 Heynemann S, Mitchell P. Developments in systemic therapies for the management of lung cancer. Intern Med J 2021;51:2012-20. [PMID: 34939294 DOI: 10.1111/imj.15609] [Reference Citation Analysis]
236 Baas P. Nivolumab Plus Ipilimumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. J Thorac Oncol 2022;17:30-3. [PMID: 34930609 DOI: 10.1016/j.jtho.2021.07.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
237 Fennell DA, Dulloo S. Chemotherapy With or Without Bevacizumab Should Be the Standard of Care for First-Line Unresectable Epithelioid Mesothelioma. J Thorac Oncol 2022;17:34-7. [PMID: 34930610 DOI: 10.1016/j.jtho.2021.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
238 Kindler HL. Systemic Therapy for Mesothelioma: Turning the Corner. JCO Oncol Pract 2021;:OP2100785. [PMID: 34932380 DOI: 10.1200/OP.21.00785] [Reference Citation Analysis]
239 Gounant V, Brosseau S, Zalcman G. Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment. Ther Adv Med Oncol 2021;13:17588359211061956. [PMID: 34917175 DOI: 10.1177/17588359211061956] [Reference Citation Analysis]
240 Cortés-Guiral D, Hübner M, Alyami M, Bhatt A, Ceelen W, Glehen O, Lordick F, Ramsay R, Sgarbura O, Van Der Speeten K, Turaga KK, Chand M. Primary and metastatic peritoneal surface malignancies. Nat Rev Dis Primers 2021;7:91. [PMID: 34916522 DOI: 10.1038/s41572-021-00326-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
241 Armato SG, Nowak AK, Francis RJ, Katz SI, Kholmatov M, Blyth KG, Gudmundsson E, Kidd AC, Gill RR. Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group. Lung Cancer 2021;164:76-83. [PMID: 35042132 DOI: 10.1016/j.lungcan.2021.12.008] [Reference Citation Analysis]
242 Lofiego MF, Cannito S, Fazio C, Piazzini F, Cutaia O, Solmonese L, Marzani F, Chiarucci C, Di Giacomo AM, Calabrò L, Coral S, Maio M, Covre A, On Behalf Of The EPigenetic Immune-Oncology Consortium Airc Epica Investigators. Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy. Epigenomes 2021;5:27. [PMID: 34968251 DOI: 10.3390/epigenomes5040027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
243 Johnson BW, Takahashi K, Cheng YY. Preclinical Models and Resources to Facilitate Basic Science Research on Malignant Mesothelioma - A Review. Front Oncol 2021;11:748444. [PMID: 34900693 DOI: 10.3389/fonc.2021.748444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
244 Pansy K, Uhl B, Krstic J, Szmyra M, Fechter K, Santiso A, Thüminger L, Greinix H, Kargl J, Prochazka K, Feichtinger J, Deutsch AJ. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions. Int J Mol Sci 2021;22:13311. [PMID: 34948104 DOI: 10.3390/ijms222413311] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
245 Curcean S, Cheng L, Picchia S, Tunariu N, Collins D, Blackledge M, Popat S, O'Brien M, Minchom A, Leach MO, Koh DM. Early Response to Chemotherapy in Malignant Pleural Mesothelioma Evaluated Using Diffusion-Weighted Magnetic Resonance Imaging: Initial Observations. JTO Clin Res Rep 2021;2:100253. [PMID: 34870249 DOI: 10.1016/j.jtocrr.2021.100253] [Reference Citation Analysis]
246 Remon J, Hendriks LEL, Bironzo P. Malignant pleural mesothelioma: new guidelines make us stronger for defeating this disease. Ann Oncol 2021:S0923-7534(21)04850-X. [PMID: 34883215 DOI: 10.1016/j.annonc.2021.11.019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
247 Absenger G, Terbuch A. Unresectable pleural mesothelioma—hope or still an unmet medical need? memo 2021;14:376-380. [DOI: 10.1007/s12254-021-00727-z] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
248 Cai X, Zhan H, Ye Y, Yang J, Zhang M, Li J, Zhuang Y. Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases. Front Genet 2021;12:785153. [DOI: 10.3389/fgene.2021.785153] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
249 Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021:S0923-7534(21)04820-1. [PMID: 34861373 DOI: 10.1016/j.annonc.2021.11.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 14.0] [Reference Citation Analysis]
250 Seal S, Simon H. Primary Pericardial Mesothelioma: A Rare but Serious Consideration. Cureus 2021. [DOI: 10.7759/cureus.19966] [Reference Citation Analysis]
251 Laune Q, Brosseau S. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma]. Bull Cancer 2021:S0007-4551(21)00437-9. [PMID: 34848048 DOI: 10.1016/j.bulcan.2021.09.013] [Reference Citation Analysis]
252 Baas P, Daumont MJ, Lacoin L, Penrod JR, Carroll R, Venkatesan S, Ubhi H, Calleja A, Snee M. Treatment patterns and outcomes for patients with malignant pleural mesothelioma in England in 2013-2017: A nationwide CAS registry analysis from the I-O Optimise initiative. Lung Cancer 2021;162:185-93. [PMID: 34823894 DOI: 10.1016/j.lungcan.2021.11.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
253 Nowak AK, Chin WL, Keam S, Cook A. Immune checkpoint inhibitor therapy for malignant pleural mesothelioma. Lung Cancer 2021;162:162-8. [PMID: 34823106 DOI: 10.1016/j.lungcan.2021.11.006] [Reference Citation Analysis]
254 Nakanishi R, Okuda K. Treatment for Malignant Pleural Mesothelioma. JJLC 2021;61:865-868. [DOI: 10.2482/haigan.61.865] [Reference Citation Analysis]
255 Lisi L, Lacal PM, Martire M, Navarra P, Graziani G. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacol Res 2021;175:105997. [PMID: 34826600 DOI: 10.1016/j.phrs.2021.105997] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
256 Gendre DAJ, Ameti E, Karenovics W, Perriraz-Mayer N, Triponez F, Serre-Beinier V. Optimization of tumor spheroid model in mesothelioma and lung cancers and anti-cancer drug testing in H2052/484 spheroids. Oncotarget 2021;12:2375-87. [PMID: 34853659 DOI: 10.18632/oncotarget.28134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
257 Sidhu C, Louw A, Gary Lee YC. Malignant Pleural Mesothelioma: Updates for Respiratory Physicians. Clin Chest Med 2021;42:697-710. [PMID: 34774176 DOI: 10.1016/j.ccm.2021.08.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Ke H, Gill AJ, McKenzie C, Kench JG, Chan RCF, Pavlakis N, Fulham M, Koh C, Kao S. Malignant Peritoneal Mesothelioma With EWSR1-ATF1 Fusion: A Case Report. JTO Clin Res Rep 2021;2:100236. [PMID: 34766064 DOI: 10.1016/j.jtocrr.2021.100236] [Reference Citation Analysis]
259 Ramundo V, Zanirato G, Aldieri E. The Epithelial-to-Mesenchymal Transition (EMT) in the Development and Metastasis of Malignant Pleural Mesothelioma. Int J Mol Sci 2021;22:12216. [PMID: 34830097 DOI: 10.3390/ijms222212216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
260 Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, Lanis M, Belcaid Z, Smith KN, Balan A, White JR, Cherry C, Ashok Sivakumar IK, Shao XM, Chan HY, Singh D, Thapa S, Illei PB, Pardoll DM, Karchin R, Velculescu VE, Brahmer JR, Ramalingam SS. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med 2021;27:1910-20. [PMID: 34750557 DOI: 10.1038/s41591-021-01541-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 13.0] [Reference Citation Analysis]
261 Aliagas E, Alay A, Martínez-Iniesta M, Hernández-Madrigal M, Cordero D, Gausachs M, Pros E, Saigí M, Busacca S, Sharkley AJ, Dawson A, Palmero R, Ruffinelli JC, Padrones S, Aso S, Escobar I, Ramos R, Llatjós R, Vidal A, Dorca E, Varela M, Sánchez-Céspedes M, Fennell D, Muñoz-Pinedo C, Villanueva A, Solé X, Nadal E. Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma. Br J Cancer 2021;125:1365-76. [PMID: 34588615 DOI: 10.1038/s41416-021-01547-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
262 Hemminki K, Försti A, Chen T, Hemminki A. Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden. BMC Cancer 2021;21:1189. [PMID: 34749677 DOI: 10.1186/s12885-021-08913-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
263 Banerji S, Meyers DE, Harlos C, Dawe DE. The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma. Curr Oncol 2021;28:4542-51. [PMID: 34898559 DOI: 10.3390/curroncol28060385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
264 Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Marmolejo D, Rezqallah A, Carbonell C, Frigola J, Amat R, Pedrola A, Dienstmann R, Felip E. Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. Sci Rep 2021;11:21357. [PMID: 34725384 DOI: 10.1038/s41598-021-00831-4] [Reference Citation Analysis]
265 Miyamoto Y, Kozuki T, Aoe K, Wada S, Harada D, Yoshida M, Sakurai J, Hotta K, Fujimoto N. JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. J Immunother Cancer 2021;9:e003288. [PMID: 34711664 DOI: 10.1136/jitc-2021-003288] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
266 Grosso F, Mannucci M, Ugo F, Ferro P, Cassinari M, Vigani A, De Angelis AM, Delfanti S, Lia M, Guaschino R, Barbero S, Roncella S, Giannoni U, Bertolotti M, Pistillo MP, Fontana V. Pilot Study to Evaluate Serum Soluble Mesothelin-Related Peptide (SMRP) as Marker for Clinical Monitoring of Pleural Mesothelioma (PM): Correlation with Modified RECIST Score. Diagnostics (Basel) 2021;11:2015. [PMID: 34829362 DOI: 10.3390/diagnostics11112015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
267 Danese MD, Daumont M, Nwokeji E, Gleeson M, Penrod JR, Lubeck D. Treatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data. Cancer Rep (Hoboken) 2021;:e1568. [PMID: 34698447 DOI: 10.1002/cnr2.1568] [Reference Citation Analysis]
268 Martorana F, Colombo I, Treglia G, Gillessen S, Stathis A. A systematic review of phase II trials exploring anti-PD-1/PD-L1 combinations in patients with solid tumors. Cancer Treat Rev 2021;101:102300. [PMID: 34688105 DOI: 10.1016/j.ctrv.2021.102300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
269 Çakılkaya P, Sørensen RR, Jürgensen HJ, Krigslund O, Gårdsvoll H, Nielsen CF, Santoni-Rugiu E, Behrendt N, Engelholm LH. The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target. Int J Mol Sci 2021;22:11452. [PMID: 34768883 DOI: 10.3390/ijms222111452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
270 Gulden J. Pleuramesotheliom: Überlebensvorteil hält mit Immuntherapie an. Deutsches Ärzteblatt Online 2021. [DOI: 10.3238/persesmo.2021.10.22.14] [Reference Citation Analysis]
271 Ghafoor A, Mian I, Wagner C, Mallory Y, Agra MG, Morrow B, Wei JS, Khan J, Thomas A, Sengupta M, Steinberg SM, Hassan R. Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene. JTO Clin Res Rep 2021;2:100231. [PMID: 34661178 DOI: 10.1016/j.jtocrr.2021.100231] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
272 Nowak AK. CONFIRMing single-drug immune checkpoint blockade efficacy in mesothelioma. Lancet Oncol 2021;22:1485-7. [PMID: 34656224 DOI: 10.1016/S1470-2045(21)00516-7] [Reference Citation Analysis]
273 Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol 2021;22:1530-40. [PMID: 34656227 DOI: 10.1016/S1470-2045(21)00471-X] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 25.5] [Reference Citation Analysis]
274 Kulkarni AA, Kratzke RA. A Turning Point for Mesothelioma Therapy. JCO Oncol Pract 2021;:OP2100608. [PMID: 34652951 DOI: 10.1200/OP.21.00608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
275 Ebbinghaus-Mier D, Ebbinghaus R, Prager HM, Schöps W, Golka K. [Mesothelioma of the tunica vaginalis of the testis-a histopathological finding with far-reaching consequences]. Urologe A 2021. [PMID: 34652478 DOI: 10.1007/s00120-021-01689-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
276 García-Sancha N, Corchado-Cobos R, Bellido-Hernández L, Román-Curto C, Cardeñoso-Álvarez E, Pérez-Losada J, Orfao A, Cañueto J. Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma. Cancers (Basel) 2021;13:5134. [PMID: 34680282 DOI: 10.3390/cancers13205134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
277 Obacz J, Yung H, Shamseddin M, Linnane E, Liu X, Azad AA, Rassl DM, Fairen-Jimenez D, Rintoul RC, Nikolić MZ, Marciniak SJ. Biological basis for novel mesothelioma therapies. Br J Cancer 2021;125:1039-55. [PMID: 34226685 DOI: 10.1038/s41416-021-01462-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
278 Laune Q, Brosseau S. [New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma]. Bull Cancer 2021:S0007-4551(21)00374-X. [PMID: 34654542 DOI: 10.1016/j.bulcan.2021.07.010] [Reference Citation Analysis]
279 Alcantara M, Fuentealba J, Soussain C. Emerging Landscape of Immunotherapy for Primary Central Nervous System Lymphoma. Cancers (Basel) 2021;13:5061. [PMID: 34680209 DOI: 10.3390/cancers13205061] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
280 Goričar K, Holcar M, Mavec N, Kovač V, Lenassi M, Dolžan V. Extracellular Vesicle Enriched miR-625-3p Is Associated with Survival of Malignant Mesothelioma Patients. J Pers Med 2021;11:1014. [PMID: 34683154 DOI: 10.3390/jpm11101014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
281 Petrelli F, Consoli F, Ghidini A, Perego G, Luciani A, Mercurio P, Berruti A, Grisanti S. Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review. Front Immunol 2021;12:720748. [PMID: 34616395 DOI: 10.3389/fimmu.2021.720748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
282 Kim RY, Mitra N, Bagley SJ, Marmarelis ME, Haas AR, Rendle KA, Vachani A. Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma. JTO Clin Res Rep 2021;2:100188. [PMID: 34590032 DOI: 10.1016/j.jtocrr.2021.100188] [Reference Citation Analysis]
283 Brustugun OT, Nilssen Y, Eide IJZ. Epidemiology and outcome of peritoneal and pleural mesothelioma subtypes in Norway. A 20 year nation-wide study. Acta Oncol 2021;60:1250-6. [PMID: 34313510 DOI: 10.1080/0284186X.2021.1955971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
284 Walsh RJ, Tan DSP. The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives. J Clin Med 2021;10:4523. [PMID: 34640541 DOI: 10.3390/jcm10194523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
285 Mangiante L, Alcala N, Di Genova A, Sexton-oates A, Gonzalez-perez A, Khandekar A, Bergstrom EN, Kim J, Giacobi C, Le Stang N, Boyault S, Cuenin C, Tabone-eglinger S, Damiola F, Voegele C, Ardin M, Michallet M, Soudade L, Delhomme TM, Poret A, Brevet M, Copin M, Giusiano-courcambeck S, Damotte D, Girard C, Hofman V, Hofman P, Mouroux J, Lacomme S, Mazieres J, de Montpreville VT, Perrin C, Planchard G, Rouquette I, Sagan C, Scherpereel A, Thivolet F, Vignaud J, Jean D, Gilg Soit Ilg A, Olaso R, Meyer V, Boland A, Deleuze J, Altmuller J, Nuernberg P, Lantuejoul S, Ghantous A, Maussion C, Courtiol P, Hernandez-vargas H, Caux C, Girard N, Lopez-bigas N, Alexandrov LB, Salle FG, Foll M, Fernandez-cuesta L. Disentangling heterogeneity of Malignant Pleural Mesothelioma through deep integrative omics analyses.. [DOI: 10.1101/2021.09.27.461908] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
286 Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, Li Z, Pan CX. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol 2021;14:156. [PMID: 34579759 DOI: 10.1186/s13045-021-01164-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 18.0] [Reference Citation Analysis]
287 Johnson B, Lee K, Cheng YY. Pre-Clinical Research Advancements Relating to Improving the Diagnosis and Treatment of Malignant Pleural Mesothelioma: A Review. Onco 2021;1:49-82. [DOI: 10.3390/onco1020006] [Reference Citation Analysis]
288 Kindler HL. Understanding the new therapeutic options for mesothelioma. Lancet Oncol 2021;22:1353-5. [PMID: 34499875 DOI: 10.1016/S1470-2045(21)00520-9] [Reference Citation Analysis]
289 Nowak AK, Jackson A, Sidhu C. Management of Advanced Pleural Mesothelioma-At the Crossroads. JCO Oncol Pract 2021;:OP2100426. [PMID: 34491782 DOI: 10.1200/OP.21.00426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
290 Zolondick AA, Gaudino G, Xue J, Pass HI, Carbone M, Yang H. Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review. Precis Cancer Med 2021;4:27. [PMID: 35098108 DOI: 10.21037/pcm-21-12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
291 Gauvain C. Essais contrôlés randomisés : quelques clés méthodologiques pour comprendre. Revue des Maladies Respiratoires Actualités 2021;13:2S55-2S62. [DOI: 10.1016/s1877-1203(21)00097-5] [Reference Citation Analysis]
292 Scherpereel A, Zalcman G, Gauvain C, Lantuejoul S, Greillier L. Prise en charge diagnostique et thérapeutique du mésothéliome pleural malin en 2021. Revue des Maladies Respiratoires Actualités 2021;13:2S193-2S202. [DOI: 10.1016/s1877-1203(21)00111-7] [Reference Citation Analysis]
293 Ripley RT. Commentary: Limitations of Data for Primary Pericardial Mesothelioma. Semin Thorac Cardiovasc Surg 2021:S1043-0679(21)00396-8. [PMID: 34469797 DOI: 10.1053/j.semtcvs.2021.08.017] [Reference Citation Analysis]
294 Reischer A, Kruger S, von Bergwelt-Baildon M. [A decade of checkpoint inhibitors: current standard of care and future trends]. Dtsch Med Wochenschr 2021;146:1108-18. [PMID: 34448187 DOI: 10.1055/a-1303-8820] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
295 Mathilakathu A, Borchert S, Wessolly M, Mairinger E, Beckert H, Steinborn J, Hager T, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Schmid KW, Walter RFH, Brcic L, Mairinger FD. Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study. Transl Lung Cancer Res 2021;10:3030-42. [PMID: 34430345 DOI: 10.21037/tlcr-21-201] [Reference Citation Analysis]
296 Liao D, Yu Y, Mei Q, Wang Z, Li X, Jia Y, Kong F. Advances in Immunotherapy of Malignant Pleural Mesothelioma. Onco Targets Ther 2021;14:4477-84. [PMID: 34429612 DOI: 10.2147/OTT.S317434] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
297 Aprile V, Lenzini A, Lococo F, Bacchin D, Korasidis S, Mastromarino MG, Guglielmi G, Palmiero G, Ambrogi MC, Lucchi M. Hyperthermic Intrathoracic Chemotherapy for Malignant Pleural Mesothelioma: The Forefront of Surgery-Based Multimodality Treatment. J Clin Med 2021;10:3801. [PMID: 34501249 DOI: 10.3390/jcm10173801] [Reference Citation Analysis]
298 Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). J Immunother Cancer 2021;9. [PMID: 34429332 DOI: 10.1136/jitc-2021-002973] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
299 Brims F. Epidemiology and Clinical Aspects of Malignant Pleural Mesothelioma. Cancers (Basel) 2021;13:4194. [PMID: 34439349 DOI: 10.3390/cancers13164194] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
300 Huppert LA, Daud AI. Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma. J Clin Oncol 2021;39:2637-9. [PMID: 34138634 DOI: 10.1200/JCO.21.00943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
301 Lapidot M, Case AE, Weisberg EL, Meng C, Walker SR, Garg S, Ni W, Podar K, Hung YP, Carrasco RD, Knott A, Gokhale PC, Sharma S, Pozhitkov A, Kulkarni P, Frank DA, Salgia R, Griffin JD, Saladi SV, Bueno R, Sattler M. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer 2021;125:582-92. [PMID: 34088988 DOI: 10.1038/s41416-021-01441-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
302 Carbotti G, Dozin B, Martini S, Giordano C, Scordamaglia F, Croce M, Filaci G, Ferrini S, Fabbi M. IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells. Cancers (Basel) 2021;13:4011. [PMID: 34439164 DOI: 10.3390/cancers13164011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
303 Yeo D, Castelletti L, van Zandwijk N, Rasko JEJ. Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma. Cancers (Basel) 2021;13:3932. [PMID: 34439085 DOI: 10.3390/cancers13163932] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
304 Lou J, Aragaki M, Bernards N, Kinoshita T, Mo J, Motooka Y, Ishiwata T, Gregor A, Chee T, Chen Z, Chen J, Kaga K, Wakasa S, Zheng G, Yasufuku K. Repeated porphyrin lipoprotein-based photodynamic therapy controls distant disease in mouse mesothelioma via the abscopal effect. Nanophotonics 2021;10:3279-94. [DOI: 10.1515/nanoph-2021-0241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
305 Pass HI. Commentary: Extended pleurectomy decortication: Step 1, standardized techniques; step 2, standardized documentation. JTCVS Tech 2021;7:331-2. [PMID: 34318282 DOI: 10.1016/j.xjtc.2021.03.026] [Reference Citation Analysis]
306 Maio M, Lahn M, Di Giacomo AM, Covre A, Calabrò L, Ibrahim R, Fox B; Siena Think Tank. A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. J Exp Clin Cancer Res 2021;40:240. [PMID: 34301276 DOI: 10.1186/s13046-021-02023-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
307 Meiller C, Montagne F, Hirsch TZ, Caruso S, de Wolf J, Bayard Q, Assié JB, Meunier L, Blum Y, Quetel L, Gibault L, Pintilie E, Badoual C, Humez S, Galateau-Sallé F, Copin MC, Letouzé E, Scherpereel A, Zucman-Rossi J, Le Pimpec-Barthes F, Jaurand MC, Jean D. Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Med 2021;13:113. [PMID: 34261524 DOI: 10.1186/s13073-021-00931-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
308 Yuan L, Sun B, Xu L, Chen L, Ou W. The Updating of Biological Functions of Methyltransferase SETDB1 and Its Relevance in Lung Cancer and Mesothelioma. Int J Mol Sci 2021;22:7416. [PMID: 34299035 DOI: 10.3390/ijms22147416] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
309 Brossel H, Fontaine A, Hoyos C, Jamakhani M, Willems M, Hamaidia M, Willems L. Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma. Cancers (Basel) 2021;13:3211. [PMID: 34199066 DOI: 10.3390/cancers13133211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
310 Désage AL, Karpathiou G, Peoc'h M, Froudarakis ME. The Immune Microenvironment of Malignant Pleural Mesothelioma: A Literature Review. Cancers (Basel) 2021;13:3205. [PMID: 34206956 DOI: 10.3390/cancers13133205] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
311 Chiu LC, Lin SM, Lo YL, Kuo SC, Yang CT, Hsu PC. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines (Basel) 2021;9:689. [PMID: 34201650 DOI: 10.3390/vaccines9070689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
312 Hiltbrunner S, Mannarino L, Kirschner MB, Opitz I, Rigutto A, Laure A, Lia M, Nozza P, Maconi A, Marchini S, D'Incalci M, Curioni-Fontecedro A, Grosso F. Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma. Front Oncol 2021;11:660039. [PMID: 34249695 DOI: 10.3389/fonc.2021.660039] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
313 Behrouzfar K, Burton K, Mutsaers SE, Morahan G, Lake RA, Fisher SA. How to Better Understand the Influence of Host Genetics on Developing an Effective Immune Response to Thoracic Cancers. Front Oncol 2021;11:679609. [PMID: 34235080 DOI: 10.3389/fonc.2021.679609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
314 Terenziani R, Zoppi S, Fumarola C, Alfieri R, Bonelli M. Immunotherapeutic Approaches in Malignant Pleural Mesothelioma. Cancers (Basel) 2021;13:2793. [PMID: 34199722 DOI: 10.3390/cancers13112793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
315 Lorenzini E, Ciarrocchi A, Torricelli F. Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations. J Clin Med 2021;10:2470. [PMID: 34199544 DOI: 10.3390/jcm10112470] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
316 Remon J, Besse B. Immunotherapy in other thoracic malignancies and uncommon populations. Transl Lung Cancer Res 2021;10:2865-7. [PMID: 34295684 DOI: 10.21037/tlcr-21-456] [Reference Citation Analysis]
317 Haakensen VD, Nowak AK, Ellingsen EB, Farooqi SJ, Bjaanæs MM, Horndalsveen H, Mcculloch T, Grundberg O, Cedres SM, Helland Å. NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. J Transl Med 2021;19:232. [PMID: 34059094 DOI: 10.1186/s12967-021-02905-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
318 Amodio V, Mauri G, Reilly NM, Sartore-Bianchi A, Siena S, Bardelli A, Germano G. Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal Cancers. Cancers (Basel) 2021;13:2638. [PMID: 34072037 DOI: 10.3390/cancers13112638] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
319 Vita E, Stefani A, Di Salvatore M, Chiappetta M, Lococo F, Margaritora S, Tortora G, Bria E. Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma. J Clin Med 2021;10:2290. [PMID: 34070352 DOI: 10.3390/jcm10112290] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
320 Napoli F, Listì A, Zambelli V, Witel G, Bironzo P, Papotti M, Volante M, Scagliotti G, Righi L. Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Cancers (Basel) 2021;13:2564. [PMID: 34073720 DOI: 10.3390/cancers13112564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
321 Dumoulin DW, Cornelissen R, Bezemer K, Baart SJ, Aerts JGJV. Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials. Vaccines (Basel) 2021;9:525. [PMID: 34069348 DOI: 10.3390/vaccines9050525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
322 Anobile DP, Bironzo P, Picca F, Lingua MF, Morena D, Righi L, Napoli F, Papotti MG, Pittaro A, Di Nicolantonio F, Gigliotti C, Bussolino F, Comunanza V, Guerrera F, Sandri A, Leo F, Libener R, Aviles P, Novello S, Taulli R, Scagliotti GV, Riganti C. Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers (Basel) 2021;13:2332. [PMID: 34066159 DOI: 10.3390/cancers13102332] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
323 Chintala NK, Restle D, Quach H, Saini J, Bellis R, Offin M, Beattie J, Adusumilli PS. CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. Lung Cancer 2021;157:48-59. [PMID: 33972125 DOI: 10.1016/j.lungcan.2021.05.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
324 Gray SG. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulm Med 2021;21:148. [PMID: 33952230 DOI: 10.1186/s12890-021-01513-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
325 Ma W, Pham B, Li T. Cancer neoantigens as potential targets for immunotherapy. Clin Exp Metastasis 2021. [PMID: 33950415 DOI: 10.1007/s10585-021-10091-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
326 Kotecha R, Tonse R, Rubens M, Appel H, Albrecht F, Kaywin P, Alley EW, Tom MC, Mehta MP. Meta-Analysis of Survival and Development of a Prognostic Nomogram for Malignant Pleural Mesothelioma Treated with Systemic Chemotherapy. Cancers (Basel) 2021;13:2186. [PMID: 34063225 DOI: 10.3390/cancers13092186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
327 Principe N, Kidman J, Lake RA, Lesterhuis WJ, Nowak AK, McDonnell AM, Chee J. Malignant Pleural Effusions-A Window Into Local Anti-Tumor T Cell Immunity? Front Oncol 2021;11:672747. [PMID: 33987104 DOI: 10.3389/fonc.2021.672747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
328 Arrieta O, Muñoz-Montaño W, Muñiz-Hernández S, Campos S, Catalán R, Soto-Molina H, Guzmán Vázquez S, Díaz-Álvarez O, Martínez-Pacheco V, Turcott JG, Ramos-Ramírez M, Cabrera-Miranda L, Barrón F, Cardona AF. Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma. Front Oncol 2021;11:641975. [PMID: 33959504 DOI: 10.3389/fonc.2021.641975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
329 Lanuti M, Lin J, Ng T, Burt BM. A year in general thoracic surgery published in the Journal of Thoracic and Cardiovascular Surgery: 2020. J Thorac Cardiovasc Surg 2021;162:253-8. [PMID: 34024614 DOI: 10.1016/j.jtcvs.2021.03.106] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
330 Gutierrez-Sainz L, Cruz P, Martinez-Recio S, Higuera O, Esteban-Rodriguez MI, Arias-Lotto F, Gonzalez RA, De Castro-Carpeño J. Malignant pleural mesothelioma: clinical experience and prognostic value of derived neutrophil-to-lymphocyte ratio and PD-L1 expression. Clin Transl Oncol 2021;23:2030-5. [PMID: 33837910 DOI: 10.1007/s12094-021-02605-w] [Reference Citation Analysis]
331 Brcic L, Mathilakathu A, Walter RFH, Wessolly M, Mairinger E, Beckert H, Kreidt D, Steinborn J, Hager T, Christoph DC, Kollmeier J, Mairinger T, Wohlschlaeger J, Schmid KW, Borchert S, Mairinger FD. Digital Gene Expression Analysis of Epithelioid and Sarcomatoid Mesothelioma Reveals Differences in Immunogenicity. Cancers (Basel) 2021;13:1761. [PMID: 33917061 DOI: 10.3390/cancers13081761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
332 Schalhorn A. Doppelte Checkpointblockade beim MPM. InFo Hämatol Onkol 2021;24:24-25. [DOI: 10.1007/s15004-021-8617-7] [Reference Citation Analysis]
333 Waterhouse DM, Nwokeji ED, Boyd M, Penrod JR, Espirito JL, Robert NJ, Daumont MJ. Treatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting. Future Oncol 2021;17:2439-48. [PMID: 33769073 DOI: 10.2217/fon-2021-0047] [Reference Citation Analysis]
334 Zauderer MG. The therapeutic implications of the genomic analysis of malignant pleural mesothelioma. Nat Commun 2021;12:1819. [PMID: 33753750 DOI: 10.1038/s41467-021-22142-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
335 Zhang M, Luo JL, Sun Q, Harber J, Dawson AG, Nakas A, Busacca S, Sharkey AJ, Waller D, Sheaff MT, Richards C, Wells-Jordan P, Gaba A, Poile C, Baitei EY, Bzura A, Dzialo J, Jama M, Le Quesne J, Bajaj A, Martinson L, Shaw JA, Pritchard C, Kamata T, Kuse N, Brannan L, De Philip Zhang P, Yang H, Griffiths G, Wilson G, Swanton C, Dudbridge F, Hollox EJ, Fennell DA. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment. Nat Commun 2021;12:1751. [PMID: 33741915 DOI: 10.1038/s41467-021-21798-w] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 19.5] [Reference Citation Analysis]
336 Dudnik E, Bar J, Moore A, Gottfried T, Moskovitz M, Dudnik J, Shochat T, Allen AM, Zer A, Rotem O, Peled N, Urban D. BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors. Front Oncol 2021;11:603223. [PMID: 33777745 DOI: 10.3389/fonc.2021.603223] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
337 Kubota Y, Kawazoe A, Shitara K. Perspective on the Immunotherapy of Gastric Cancer. Cancer Immunotherapy 2021. [DOI: 10.1007/13905_2021_5] [Reference Citation Analysis]
338 Huang Y, Meng Q. [Research Progress of Immune Checkpoint Inhibitors 
in Malignant Pleural Mesothelioma]. Zhongguo Fei Ai Za Zhi 2021;24:441-6. [PMID: 34157803 DOI: 10.3779/j.issn.1009-3419.2021.102.18] [Reference Citation Analysis]